WO2017048629A1 - Antibodies for generating anti-inflammatory macrophage and related uses - Google Patents
Antibodies for generating anti-inflammatory macrophage and related uses Download PDFInfo
- Publication number
- WO2017048629A1 WO2017048629A1 PCT/US2016/051290 US2016051290W WO2017048629A1 WO 2017048629 A1 WO2017048629 A1 WO 2017048629A1 US 2016051290 W US2016051290 W US 2016051290W WO 2017048629 A1 WO2017048629 A1 WO 2017048629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- cells
- cathepsin
- macrophages
- Prior art date
Links
- 210000002540 macrophage Anatomy 0.000 title claims abstract description 73
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 25
- 210000004027 cell Anatomy 0.000 claims abstract description 135
- 210000004322 M2 macrophage Anatomy 0.000 claims abstract description 110
- 238000000034 method Methods 0.000 claims abstract description 89
- 210000002798 bone marrow cell Anatomy 0.000 claims abstract description 69
- 108090000617 Cathepsin G Proteins 0.000 claims abstract description 55
- 102000004173 Cathepsin G Human genes 0.000 claims abstract description 55
- 210000001616 monocyte Anatomy 0.000 claims abstract description 50
- 230000001939 inductive effect Effects 0.000 claims abstract description 22
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 20
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 238000012258 culturing Methods 0.000 claims abstract description 12
- 230000027455 binding Effects 0.000 claims description 33
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 16
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 12
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 206010025135 lupus erythematosus Diseases 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 8
- 108010045374 CD36 Antigens Proteins 0.000 claims description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 6
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 6
- -1 MHCII Proteins 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 239000002771 cell marker Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 101000933179 Homo sapiens Cathepsin G Proteins 0.000 claims description 2
- 102000049320 CD36 Human genes 0.000 claims 1
- 102100025975 Cathepsin G Human genes 0.000 claims 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 abstract description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 230000028993 immune response Effects 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 2
- 239000000556 agonist Substances 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 25
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 18
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 18
- 230000004069 differentiation Effects 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 210000001185 bone marrow Anatomy 0.000 description 15
- 108090000174 Interleukin-10 Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 12
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241000713666 Lentivirus Species 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000002243 precursor Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 238000000692 Student's t-test Methods 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 206010018364 Glomerulonephritis Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000011813 knockout mouse model Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 102000053028 CD36 Antigens Human genes 0.000 description 5
- 101710190174 E3 ubiquitin-protein ligase MYLIP Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102100031788 E3 ubiquitin-protein ligase MYLIP Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 208000007465 Giant cell arteritis Diseases 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 201000001981 dermatomyositis Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 206010043207 temporal arteritis Diseases 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 3
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 2
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 101100273320 Mus musculus Ctsg gene Proteins 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000002702 ribosome display Methods 0.000 description 2
- 108010078070 scavenger receptors Proteins 0.000 description 2
- 102000014452 scavenger receptors Human genes 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009392 systemic autoimmunity Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101710149506 28 kDa protein Proteins 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 102100021723 Arginase-1 Human genes 0.000 description 1
- 101710129000 Arginase-1 Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 230000024704 B cell apoptotic process Effects 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 101710137943 Complement control protein C3 Proteins 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000666171 Homo sapiens Protein-glutamine gamma-glutamyltransferase 2 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108010052014 Liberase Proteins 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100034400 Nuclear factor of activated T-cells, cytoplasmic 2 Human genes 0.000 description 1
- 101710151538 Nuclear factor of activated T-cells, cytoplasmic 2 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 101800001707 Spacer peptide Proteins 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710152003 Suppressor of silencing P0 Proteins 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101150109894 TGFA gene Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010042430 galactose receptor Proteins 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000008269 immune-complex glomerulonephritis Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- WLHQHAUOOXYABV-UHFFFAOYSA-N lornoxicam Chemical compound OC=1C=2SC(Cl)=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 WLHQHAUOOXYABV-UHFFFAOYSA-N 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000003003 monocyte-macrophage precursor cell Anatomy 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Definitions
- the system of checks and balances operates, for example, by balancing effector and regulatory T-cells and/or pro-inflammatory and anti-inflammatory macrophages.
- one or the other arm of an otherwise balanced system may need to be favored.
- Such control has become one of the major goals in immunology for the treatment of autoimmunity and cancer.
- the invention provides isolated or purified anti-Cathepsin G
- CTSG antibodies have the same binding specificity as that of a reference anti-CTSG antibody having (1) heavy chain CDRl, CDR2 and CDR3 sequences respectively shown in GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and (2) light chain CDRl, CDR2 and CDR3 sequences respectively shown in SGSIASNS (SEQ ID NO:7), EN , and QSYDSNFHWV (SEQ ID NO:8).
- Some of the antibodies contain heavy chain CDRl , CDR2 and CDR3 sequences that are substantially identical to GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6), respectively; and light chain CDRl , CDR2 and CDR3 sequences that are substantially identical to SGSIASNS (SEQ ID NO: 7), ENN, and
- QSYDSNFHWV (SEQ ID NO:8), respectively.
- Some antibodies contain heavy chain CDRl, CDR2 and CDR3 sequences that are respectively identical to GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and light chain CDRl, CDR2 and CDR3 sequences that are respectively identical to SGSIASNS (SEQ ID NO:7), ENN, and QSYDSNFHWV (SEQ ID NO:8) (SEQ ID NO:8).
- Some antibodies of the invention contain heavy chain and light chain variable region sequences that are substantially identical to SEQ ID NO:2 and SEQ ID NO:3, respectively. Some antibodies contain heavy chain and light chain variable region sequences that are at least 90% or 95% identical to SEQ ID NO:2 and SEQ ID NO:3, respectively. Some of the antibodies contain heavy chain and light chain variable region sequences show in SEQ ID NO:2 and SEQ ID NO:3, respectively.
- the antibody is a scFv having an amino acid sequence that is substantially identical to SEQ ID NO: 1. Some of the scFvs have an amino acid sequence that is at least 90% or 95% identical to SEQ ID NO: 1. In one embodiment, the scFv has a sequence shown in SEQ ID NO: 1.
- the invention provides methods for inducing formation of antiinflammatory M2 macrophages.
- the methods entail contacting a population of bone marrow cells or monocytes with an anti-Cathepsin G antibody under conditions sufficient to induce formation of anti-inflammatory macrophage, wherein the anti-Cathepsin G antibody has the same binding specificity as that of a reference antibody comprising (a) heavy chain CDRl, CDR2 and CDR3 sequences respectively shown in GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and (b) light chain CDRl , CDR2 and CDR3 sequences respectively shown in SGSIASNS (SEQ ID NO:7), ENN, and
- the employed bone marrow cells are human bone marrow cells.
- the contacting occurs in vitro by culturing the population of bone marrow cells or monocytes in the presence of the anti- Cathepsin G antibody.
- the cells are cultured with the antibody for about 4 to 20 days.
- Some of the methods further include isolating CD1 lb- cells from the cultured cell population.
- Some methods further include detecting in the cultured cell population at least one cellular marker expressed by M2 macrophage, e.g., CD36, MHCII, CD 14, or ARG-1.
- contacting the cells with the antibody occurs in vivo in a subject.
- the subject is afflicted with an autoimmune disease, and the antibody is administered to the subject via a pharmaceutical composition.
- Some methods of the invention use an anti-Cathepsin G antibody having an amino acid sequence that is substantially identical to SEQ ID NO: l .
- Some related embodiments of the invention provide populations of anti-inflammatory M2 macrophages produced by the methods of the invention.
- the invention provides methods for treating or ameliorating the symptoms of an autoimmune disease in a subject.
- the methods involve administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an anti-Cathepsin G antibody.
- the anti-Cathepsin G antibody used in the methods typically has the same binding specificity as that of a reference antibody comprising (a) heavy chain CDRl, CDR2 and CDR3 sequences respectively shown in GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO: 5), and AREEEQQFSLDY (SEQ ID NO:6); and (b) light chain CDRl, CDR2 and CDR3 sequences respectively shown in SGSIASNS (SEQ ID NO:7), EN , and QSYDSNFHWV (SEQ ID NO: 8).
- the employed antibody has heavy chain CDRl , CDR2 and CDR3 sequences that are respectively identical to GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and light chain CDRl , CDR2 and CDR3 sequences that are respectively identical to SGSIASNS (SEQ ID NO:7), ENN, and QSYDSNFHWV (SEQ ID NO:8) (SEQ ID NO:8).
- the employed antibody has heavy chain and light chain variable region sequences show in SEQ ID NO:2 and SEQ ID NO:3, respectively.
- the employed antibody is a scFv having an amino acid sequence that is substantially identical to SEQ ID NO: l .
- the employed anti-Cathepsin G antibody is a scFv fragment shown in SEQ ID NO: l .
- the invention provides methods for obtaining antiinflammatory M2 macrophages from a population of bone marrow cells or monocytes. These methods entail (a) introducing into the bone marrow cells or monocytes a plurality of vectors expressing a library of antibodies, (b) culturing the cells harboring the vectors under conditions to express the library of antibodies, and (c) selecting one or more macrophages from the cells expressing the library of antibodies.
- the library of antibodies are unbiased, e.g., unbiased scFv antibody library.
- the employed antibodies are biased, e.g., antibodies recognizing CTSG.
- the antibodies are expressed from a lentiviral based vector.
- the employed cells are CD34 + bone marrow cells.
- selection of M2 macrophages is based on cell morphology.
- selection of M2 macrophages is based on expression of one or more M2 surface markers.
- Some methods of the invention further include isolating the antibody-expressing vectors from the selected M2 macrophages. These methods allow one to obtain novel M2 macrophage-inducing antibody agents that can be readily used in various therapeutic applications described herein, e.g., treating autoimmune diseases.
- Figure 1 shows selection of an agonist antibody that induces macrophage cell differentiation.
- A Scheme of the phenotype selection. The selection starts with a human scFv phage library (10 9 members). ScFv genes were transferred to a lentiviral vector to make lentiviral intra-body libraries. Total mouse bone marrow cells were infected with the antibody library and plated on soft agar.
- B After 2 weeks of incubation, 7 colonies with compact morphologies had grown.
- C, D These colonies were harvested and the antibody genes were recovered by PCR. One sequence was present in all colonies and was used for further studies. H&E staining of cells from the colonies showed cells with the classical morphologies of macrophages.
- Figure 2 shows identification of a novel antigen recognized by LKAb.
- A Both commercial anti-CTSG antibody and LKAb bound to a 28 kDa protein in Western blots of lysates from cells overexpressing CTSG.
- B Lysates of mouse bone marrow cells were incubated with LKAb for immuno-purification. Eluates from these immune complexes bound to the commercial anti-CTSG antibody in Western blots.
- C A CTSG enzymatic assay showed that CTSG enzyme activity was present in the eluates and mouse bone marrow total lysates.
- D Mouse bone marrow was incubated for two days with lentiviruses containing CTSG shRNA.
- FIG. 3 shows that LKAb induced anti-inflammatory M2 macrophage differentiation.
- A Mouse bone marrow cells were incubated with LKAb at the indicated concentrations (l-10( ⁇ g/ml) for 6 days. Cells were then stained with anti-CDl lb and anti- CD1 l c and analyzed by FACS. Encircled shapes identify positive macrophage populations. LKAb induces differentiation of CD1 lb+ macrophages but not CD1 lc+ dendritic cells. This process is dose dependent.
- B Mouse total bone marrow cells were separated using CD1 lb- specific magnetic beads, and the isolated CD 1 lb-positive or -negative populations were incubated with LKAb or M-CSF for 6 days.
- C Mouse bone marrow was incubated with medium, LKAb or M-CSF for 6 days. Cells were then stained with anti-CDl 6/32 and anti-CD86 as Ml macrophage markers, and anti-CD36, anti-MHCII and anti-CD 14 as M2 macrophage markers. Encircled shapes mark M2 type specific populations. The macrophages induced by LKAb selectively expressed M2 type markers.
- D Mouse bone marrow was induced by LKAb antibody or M-CSF for 6 days.
- FIG. 4 shows that CTSG, CD14 and NAFAT play a key role in LKAb- dependent M2 macrophage differentiation.
- A Bone marrow cells from wild type, CTSG knockout, CD 14 knockout mice or NFAT knockout mice were incubated with medium, LKAb or M-CSF for 6 days. Cells were then stained with anti-CD 14 and anti-F4/80. FACS analysis showed CD14 and F4/80 expression was increased by LKAb in normal mice.
- CD 14 and F4/80 expression was significantly reduced in both the CTSG and CD 14 knockout mice.
- CD 14 and F4/80 expression was also reduced in NFATcl, but not in NFATc2:CD4 Cre , knockout mice. The percentages of M2 macrophages are shown (bottom). *P ⁇ 0.05 (Student's t-test).
- B Wild type mouse bone marrow cells were incubated with LKAb, a CTSG inhibitor, or both, and CTSG activity was determined. The antibody-induced reduction of CTSG activity was comparable to that of the inhibitor.
- C Critical cell surface components and their downstream signaling pathways potentially involved in macrophage differentiation mediated by LKAb (pictured here as bound to CTSG).
- FIG. 5 shows that LKAb induces human bone marrow cells to differentiate into M2 macrophages.
- Human total bone marrow was incubated with medium, LKAb or M-CSF for 6 days.
- Cells were then stained with anti-CDl lb and anti-CD64 as Ml type markers, and anti-CD 14, anti-CD206 and anti-CD200R as M2 markers. Encircled shapes mark the M2 type specific populations.
- LKAb also induced human bone marrow to differentiate into anti-inflammatory macrophages.
- FIG. 6 shows that treatment with LKAb reduced lupus-like disease in MRL-lpr mice.
- Mice (6-7/group) were injected i.p. with LKAb or PBS (from the age of 6 weeks until termination of the experiment at 20 weeks) and followed for manifestations of disease.
- A IgG2a anti-chromatin autoantibody levels determined by ELISA at 12 weeks of age.
- B Progression of lymphadenopathy between 12 and 16 weeks of age assessed by palpation of axillary and salivary lymph nodes (LNs) and scored on a 0-4 scale.
- C Kidney disease determined by histological examination for glomerulonephritis (GN) at 20 weeks of age. Representative images for treated and control mice are shown.
- Figure 7 shows LKAb's target identification by mass spectrometry.
- A Cell lysates of mouse bone marrow were incubated with LKAb for immunoprecipitation. Immuno-precipitated eluates were separated on SDS/PAGE gels that were silver-stained.
- B, C Nano-LC-MS/MS analysis identified several candidates as antigen.
- Figure 8 shows LKAb activated signaling pathways.
- Mouse bone marrow cells were incubated with LKAb, M-CSF or GM-CSF and analyzed by Western blot with antibodies specific for phospho-AKT, ERK and p38.
- FIG. 9 shows that LKAb-induced macrophage differentiation requires CD 14 but not TLR4.
- Mouse bone marrow cells from C3H/HeOuJ (wild type), C3H/HeJ (TLR4 mutation) or C57BL/10ScNJ (TLR4 knockout) mice were incubated with LKAb, M-CSF or vehicle (C3H/HeOuJ only) for 6 days. Cells were then stained with anti-CD36 or anti- CD16/32. There is no macrophage differentiation in cells from CD14 (-/-) mice incubated with LKAb.
- the present invention is predicated in part on the studies undertaken by the present inventors to obtain antibody agonists that can selectively induce formation of antiinflammatory M2 macrophages.
- the inventors used an unbiased intracellular combinatorial library of antibodies and identified an antibody (termed “LKAb” herein) that induces bone marrow cells to differentiate into M2 macrophages.
- LKAb an antibody that induces bone marrow cells to differentiate into M2 macrophages.
- the inventors also found that the primary target of the antibody is Cathepsin G (CTSG), and that LKAb inhibited CTSG activity by 50%. It was additionally observed that the requirements for efficient macrophage polarization by this antibody include the presence of CTSG and CD 14 that appear to operate via p38, a classical marker for macrophage differentiation.
- CTSG Cathepsin G
- CTSG was classically thought to be an effector molecule secreted by activated PMNs.
- the antibodies identified by the inventors were found to be therapeutically effective in blocking autoimmunity in a classic mouse model of spontaneous systemic lupus erythematosus (SLE).
- CTSG The exact role of CTSG in the unanticipated function of inducing antiinflammatory M2 macrophages is not yet fully understood. However, the observations by the inventors suggest that this effect is dependent on inhibition of CTSG proteolytic activity, upregulation of CD14, and activation of NFAT-dependent signaling. The efficacy of this antibody in reducing nephritis in a mouse model of lupus suggests that a similar treatment can be applicable to several inflammatory syndromes in which inflammatory macrophages frequently predominate and mediate tissue damage in afflicted organs.
- the present invention provides specific antibody agents that are capable of inducing formation of M2 macrophages from monocytes or bone marrow cells.
- the invention also provides methods for generating M2 macrophages from bone marrow cells with a library of unbiased antibodies, CTSG biased antibodies, or the specific anti-CTSG antibodies exemplified herein.
- the invention further provides methods of using the identified anti-CTSG antibodies and derivatives therefrom for treating autoimmunity and for suppressing undesired immune responses.
- antibody refers to polypeptide chain(s) which exhibit a strong monovalent, bivalent or polyvalent binding to a given antigen, epitope or epitopes.
- antibodies or antigen-binding fragments used in the invention can have sequences derived from any vertebrate, camelid, avian or pisces species. They can be generated using any suitable technology, e.g., hybridoma technology, ribosome display, phage display, gene shuffling libraries, semi-synthetic or fully synthetic libraries or combinations thereof.
- antibody as used in the present invention includes intact antibodies, antigen-binding polypeptide fragments and other designer antibodies that are described below or well known in the art (see, e.g., Serafini, J Nucl. Med. 34:533-6, 1993).
- An intact "antibody” typically comprises at least two heavy (H) chains (about 50- 70 kD) and two light (L) chains (about 25 kD) inter-connected by disulfide bonds.
- the recognized immunoglobulin genes encoding antibody chains include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes.
- Light chains are classified as either kappa or lambda.
- Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
- Each heavy chain of an antibody is comprised of a heavy chain variable region (VH) and a heavy chain constant region.
- the heavy chain constant region is comprised of three domains, CHI , C H2 and C ⁇ 3 ⁇
- Each light chain is comprised of a light chain variable region (VL) and a light chain constant region.
- the light chain constant region is comprised of one domain, CL.
- the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
- the constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system and the first component (Clq) of the classical complement system.
- VH and VL regions of an antibody can be further subdivided into regions of hypervariability, also termed complementarity determining regions (CDRs), which are interspersed with the more conserved framework regions (FRs).
- CDRs complementarity determining regions
- FRs framework regions
- Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- the locations of CDR and FR regions and a numbering system have been defined by, e.g., Kabat et ah, Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, U.S. Government Printing Office (1987 and 1991).
- Antibodies to be used in the invention also include antibody fragments or antigen-binding fragments which contain the antigen-binding portions of an intact antibody that retain capacity to bind the cognate antigen.
- antibody fragments include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab') 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an intact antibody; (v) disulfide stabilized Fvs (dsFvs) which have an interchain disulfide bond engineered between structurally conserved framework regions; (vi) a single domain antibody (dAb) which consists of a V H domain (see, e.g., Ward et
- Antibodies suitable for practicing the present invention also encompass single chain antibodies.
- the term "single chain antibody” refers to a polypeptide comprising a VH domain and a VL domain in polypeptide linkage, generally linked via a spacer peptide, and which may comprise additional domains or amino acid sequences at the amino- and/or carboxyl-termini.
- a single-chain antibody may comprise a tether segment for linking to the encoding polynucleotide.
- a single chain variable region fragment (scFv) is a single-chain antibody.
- a scFv Compared to the VL and VH domains of the Fv fragment which are coded for by separate genes, a scFv has the two domains joined (e.g., via recombinant methods) by a synthetic linker. This enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules.
- Antibodies that can be used in the practice of the present invention also encompass single domain antigen-binding units which have a camelid scaffold.
- Animals in the camelid family include camels, llamas, and alpacas.
- Camelids produce functional antibodies devoid of light chains.
- Fabs classical antigen-binding molecules
- scFvs single chain variable fragments
- the various antibodies or antigen-binding fragments described herein can be produced by enzymatic or chemical modification of the intact antibodies, or synthesized de novo using recombinant DNA methodologies, or identified using phage display libraries. Methods for generating these antibodies or antigen-binding molecules are all well known in the art. For example, single chain antibodies can be identified using phage display libraries or ribosome display libraries, gene shuffled libraries (see, e.g., McCafferty et al., Nature 348:552-554, 1990; and U.S. Pat. No. 4,946,778).
- scFv antibodies can be obtained using methods described in, e.g., Bird et al., Science 242:423-426, 1988; and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988.
- Fv antibody fragments can be generated as described in Skerra and Pluckthun, Science 240: 1038-41 , 1988.
- Disulfide- stabilized Fv fragments (dsFvs) can be made using methods described in, e.g., Reiter et al., Int. J. Cancer 67: 1 13-23, 1996.
- single domain antibodies can be produced by a variety of methods described in, e.g., Ward et al., Nature 341 :544-546, 1989; and Cai and Garen, Proc. Natl. Acad. Sci. USA 93:6280-85, 1996.
- Camelid single domain antibodies can be produced using methods well known in the art, e.g., Dumoulin et al., Nature Struct. Biol. 1 1 :500-515, 2002; Ghahroudi et al., FEBS Letters 414:521-526, 1997; and Bond et al., J Mol Biol. 332:643-55, 2003.
- antigen-binding fragments e.g., Fab, F(ab') 2 or Fd fragments
- Fab, F(ab') 2 or Fd fragments can also be readily produced with routinely practiced immunology methods. See, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1998.
- the term "contacting" has its normal meaning and refers to combining two or more agents (e.g., polypeptides or phage), combining agents and cells, or combining two populations of different cells. Contacting can occur in vitro, e.g., mixing two polypeptides or mixing a population of antibodies with a population of cells in a test tube or growth medium. Contacting can also occur in a cell or in situ, e.g., contacting two polypeptides in a cell by coexpression in the cell of recombinant polynucleotides encoding the two
- polypeptides or in a cell lysate.
- Contacting can also occur in vivo inside a subject, e.g., via targeted delivery of an antibody to a specific group of cells.
- nucleic acids or polypeptide sequences refer to two or more sequences or subsequences that are the same.
- Two sequences are “substantially identical” if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection.
- the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length.
- a "ligand” is a molecule that is recognized by a particular antigen, receptor or target molecule.
- ligands that can be employed in the practice of the present invention include, but are not restricted to, agonists and antagonists for cell membrane receptors, toxins and venoms, viral epitopes, hormones, hormone receptors, polypeptides, peptides, enzymes, enzyme substrates, cofactors, drugs (e.g. opiates, steroids, etc.), lectins, sugars, polynucleotides, nucleic acids, oligosaccharides, proteins, and monoclonal antibodies.
- the ligand is a molecule that specifically binds to a monocyte surface marker.
- M2 macrophages are one of two main groups of macrophages.
- M2 macrophages function in constructive processes like wound healing and tissue repair, and turn off damaging immune system activation by producing anti-inflammatory cytokines.
- M2 is the phenotype of resident tissue
- M2 macrophages produce high levels of IL-10, TGF-beta and low levels of IL-12.
- the names Ml and M2 were chosen because Ml and M2 macrophages promote Thl and Th2 responses, respectively. Products of Thl and Th2 responses (e.g., IFN- ⁇ , IL-4) also down regulate M2 and Ml activity, respectively.
- Monocytes are a type of leukocytes (white blood cells) and are part of the innate immune system of vertebrates including all mammals. Monocytes constitute 2% to 10% of all leukocytes in the human body. They constitute between three to eight percent of the leukocytes in the blood. Half of them are stored as a reserve in the spleen. Monocytes play multiple roles in immune function. Such roles include: (1) replenishing resident
- Monocytes under normal states, and (2) in response to inflammation signals. Monocytes can move quickly (approx. 8-12 hours) to sites of infection in the tissues and
- Monocytes are produced by the bone marrow from precursors called monoblasts, bipotent cells that differentiated from hematopoietic stem cells. Monocytes circulate in the bloodstream for about one to three days and then typically move into tissues throughout the body.
- receptor broadly refers to a molecule that has an affinity for a given ligand. Receptors may-be naturally-occurring or manmade molecules. Also, they can be employed in their unaltered state or as aggregates with other species. Receptors may be attached, covalently or noncovalently, to a binding member, either directly or via a specific binding substance. A typical example of receptors which can be employed in the practice of the invention is cell surface receptor.
- subject refers to human and non-human animals (especially non- human mammals). In addition to human, it also encompasses other non-human animals such as cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys.
- target refers to a molecule or biological cell of interest that is to be analyzed or detected, e.g., a ligand such as a cytokine or hormone, a polypeptide, a cellular receptor or a cell.
- a cell has been "transformed” by exogenous or heterologous polynucleotide when such polynucleotide has been introduced inside the cell.
- the transforming DNA may or may not be integrated (covalently linked) into the genome of the cell.
- the transforming polynucleotide may be maintained on an episomal element such as a plasmid.
- a stably transformed cell is one in which the transforming polynucleotide has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication.
- a "clone” is a population of cells derived from a single cell or common ancestor by mitosis.
- a "cell line” is a clone of a primary cell that is capable of stable growth in vitro for many generations.
- the invention provides novel M2 macrophage-inducing antibodies that can convert bone marrow cells (e.g., CD34 + cells) or monocytes into anti-inflammatory macrophage.
- These agonist antibodies have the same binding specificity as that of a specific anti-CTSG scFv antibody (“LKAb") identified herein.
- LKAb specific anti-CTSG scFv antibody
- antibody LKAb can induce M2 macrophage formation from both human and mouse bone marrow cells (see, e.g., Figs. 3 and 5).
- This scFv antibody has an amino acid sequence shown in SEQ ID NO: 1.
- the sequences of the heavy chain and the light chain portions of the scFv are respectively shown in SEQ ID NOs:2 and 3.
- the CDR sequences of the heavy chain variable region of this antibody are GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQF SLD Y (SEQ ID NO:6).
- the CDR sequences of its light chain variable region are SGSIASNS (SEQ ID NO:7), ENN, and QSYDSNFHWV (SEQ ID NO:8).
- the antibodies of the invention for inducing M2 macrophage are preferably monoclonal antibodies like the antibodies exemplified in the Examples below.
- the antibodies have the same binding specificity as that of the LKAb agonist antibody and compete with the LKAb antibody for binding to Cathepsin G.
- some agonist antibodies of the invention can also contain other antibody sequences fused to the variable region sequences.
- the antibodies can contain an Fc portion of IgG.
- the antibodies can also be conjugated, covalently or noncovalently, to another entity that specifically targets a surface antigen, receptor or marker on monocyte cells.
- Some M2 macrophage-inducing agonist antibodies of the invention harbor variable region sequences that are substantially identical (e.g., at least 90% or 95% identical) to that of the LKAb antibody.
- Some other agonist antibodies have all CDR sequences in their variable regions of the heavy chain and light chain that are respectively identical or substantially identical (e.g., at least 90% or 95% identical) to the corresponding CDR sequences of the LKAb agonist antibody.
- the agonist antibody has its entire heavy chain and light chain variable region sequences respectively identical to the corresponding variable region sequences of the LKAb antibody.
- the antibodies contain amino acid residues in the framework portions of the variable regions that are different from the corresponding amino acid residues of the LKAb antibody.
- the agonist antibodies of the invention can undergo non-critical amino-acid substitutions, additions or deletions in the variable region without loss of binding specificity or effector functions, or other modifications that do not cause intolerable reduction of binding affinity or CTSG-inhibiting activities.
- antibodies incorporating such alterations exhibit substantial sequence identity to the LKAb antibody.
- the mature light chain variable regions of some of the agonist antibodies of the invention have at least 75%, at least 85% or at least 90% sequence identity to the sequence of the mature light chain variable region of the LKAb antibody.
- the mature heavy chain variable regions of the antibodies typically show at least 75%, at least 85% or at least 90% sequence identity to the sequence of the mature heavy chain variable region of the LKAb antibody.
- the antibodies typically have their entire variable region sequences that are substantial identical (e.g., at least 75%, 85%, 90%, 95%, or 99%) to the corresponding variable region sequences of the LKAb antibody.
- Some M2 macrophage-inducing agonist antibodies of the invention have the same binding specificity but improved affinity or CTSG-inhibiting activities if compared with the LKAb antibody.
- the agonist antibodies of the invention can be generated in accordance with routinely practiced immunology methods. Some of such methods are exemplified herein in the Examples.
- M2 macrophages are generated from monocytes or bone marrow cells (e.g., CD34 + cells) with a specific M2 macrophage-inducing antibody. Any of the agonist antibodies described herein can be used in the therapeutic methods of the invention for generating M2 macrophages in vivo or in vitro.
- M2 macrophages can be further divided into subsets M2a, M2b, and M2c based on gene expression profiles (Mantovani et al., Trends Immunol. 25:677-86, 2004).
- the M2a subtype is elicited by IL-4 or IL-13 (common IL-4R- alpha, CD124).
- the M2b is elicited by IL-1R ligands or exposure to immune complexes plus LPS.
- the M2c subtype can be elicited by IL-10, TGF-beta and glucocorticoid hormones.
- the fourth type of macrophage M2d is characterized by an IL-l Ohigh, IL-121ow M2 profile with some features of tumor-associated macrophages (TAMs).
- TAMs tumor-associated macrophages
- the M2d subtype has phenotypic and functional attributes similar to ovarian TAMs but distinct from M2a-c.
- the M2 macrophages produced by methods of the invention can include one or more of the subsets of M2 macrophages.
- the methods involve contacting a M2 macrophage-inducing antibody described herein with a population of monocytes or monocyte precursor cells (e.g., bone marrow cells) isolated from a subject under appropriate conditions as exemplified herein to facilitate the conversion.
- monocytes or monocyte precursor cells e.g., bone marrow cells
- the monocyte-containing samples can be maintained and cultured in any physiologically-acceptable solution suitable for the collection and/or culture of the cells.
- human bone marrow cells can be cultured in StemSpan serum-free media (STEMCELL Technologies) as exemplified herein.
- Suitable culture media include, e.g., a saline solution (e.g., phosphate-buffered saline, Kreb's solution, modified Kreb's solution, Eagle's solution, 0.9% NaCl, etc.), and a culture medium (e.g., DMEM, H.DMEM, etc.), and the like.
- the solution can contain one or more tissue-degrading enzymes, e.g., a metalloprotease, a serine protease, a neutral protease, a hyaluronidase, an RNase, or a DNase, or the like.
- Such enzymes include, but are not limited to, collagenases (e.g., collagenase I, II, III or IV, a collagenase from Clostridium histolyticum, etc.); dispase, thermolysin, elastase, trypsin, LIBERASE, hyaluronidase, and the like.
- the solution can further include a bacteriocidal ly or bacteriostatically effective amount of an antibiotic.
- antibiotics examples include a macrolide (e.g., tobramycin), a cephalosporin (e.g., cephalexin, cephradine, cefuroxime, cefprozil, cefaclor, cefixime or cefadroxil), a clarithromycin, an erythromycin, a penicillin (e.g., penicillin V) or a quinolone (e.g., ofloxacin, ciprofloxacin or norfloxacin), a tetracycline, a streptomycin, and etc.
- a macrolide e.g., tobramycin
- cephalosporin e.g., cephalexin, cephradine, cefuroxime, cefprozil, cefaclor, cefixime or cefadroxil
- a clarithromycin an erythromycin
- a penicillin e.g., penicillin V
- a quinolone e.g
- the isolated or cultured monocyte or precursor cells can also be contacted with another agent that promotes monocyte differentiation into M2 macrophage.
- the population of monocytes or precursors can be stimulated with the cytokines noted above for eliciting different M2 subtypes (e.g., IL-4 or IL-10).
- M2 subtypes e.g., IL-4 or IL-10
- a cytokine cocktail for inducing M2 macrophage from human bone marrow cells is exemplified herein.
- the cells can also be stimulated with macrophage colony stimulating factor (M-CSF).
- M-CSF macrophage colony stimulating factor
- M-CSF has been shown to polarize monocytes towards M2 macrophages (Jaguin et al., Cell Immunol. 281 :51-61, 2013).
- contacting the monocyte cell population with the stimulating cytokine such as M-CSF can be performed prior to, simultaneously with or subsequent to treatment with the antibody.
- concentration of each of the cytokines or agents in the culture medium can be in the range of, e.g., about 0.01 to 1 x 10 s U/ml.
- the culture medium can further contain serum or plasma.
- the amount of serum or plasma can be present at concentration of, e.g., about 0 to 20% by volume, preferably more than 0 to 10% by volume.
- the in vitro induced M2 macrophage population can be further subject to analysis for expression of M2 markers and enrichment for M2 macrophages.
- the cells can be examined for expression of "anti-inflammatory" cytokine expression profile, which includes high levels of IL-10 and IL-1RA and low expression of IL-12.
- M2 macrophages also express high levels of scavenger mannose and galactose receptors.
- the cells can also be examined for cytokine profiles indicative of the different subtypes of M2 macrophages.
- M2a macrophages produce IL-10, TGFp and IL-lra
- M2b macrophages produce IL-1 , IL-6, IL-10 and TGFa
- M2c macrophages produce IL-10 and TGFp
- M2d macrophages produce IL-10, IL-12, TNFa and TNFp.
- M2 macrophages also have distinct chemokine and chemokine receptor profiles unlike that of Ml macrophages.
- M2 macrophages expresses chemokines CCL17, CCL22 and CCL24 while Ml macrophages secret the TH1 cell-attracting chemokines CXCL9 and CXCL10.
- the culture of a cell population in the presence of the agonist antibody and/or other agents can be performed in accordance with standard cell culturing protocols well known in the art. Some specific procedures for generating M2 macrophages from bone marrow cells are exemplified herein.
- the isolated bone marrow cells or monocyte population are contacted with an effective amount of an antibody having the same binding specificity as that of LKAb agonist antibody under appropriate conditions to facilitate the conversion.
- the antibody is contacted with the cells in vitro.
- the cell population can be cultured at a concentration of about lxl O 2 , lxlO 3 , lxl O 4 , lxlO 5 , lxlO 6 , lxlO 7 , lxlO 8 cells/ml or higher.
- the bone marrow cells or monocytes can be cultured in the presence of an effective amount of the antibody, e.g., at a concentration of 0.1 , 0.25, 0.5, 1.0, 2.5, 5.0, 10, 25, 50, 100 ⁇ g/ml or higher.
- the contacting can last for a sufficient period of time, e.g., at least 12 hours, 1 day, 2 days, 4 days, 6 days, 10 days, 25 days, 50 days, 75 days, 100 days or longer.
- the cells can be examined along the process for molecular markers and/or morphology indicative of the presence of M2 macrophages as exemplified herein.
- the cell culture may be performed under known culture conditions, and the conditions which are used in normal cell culture can be applied.
- culture can be performed under the conditions of 37°C and 5% C0 2 .
- Cells can be diluted by adding a fresh medium to a cell culture liquid at a suitable time interval, a medium can be exchanged with a fresh medium, or a cell culture instrument can be exchanged.
- the culturing period for converting the bone marrow cells into M2 macrophages can be, e.g., from 1 to 100 days, 2 to 75 days, 3-50 days, or 4-25 days.
- the bone marrow cells are cultured in the presence of the agonist antibody and other agents for a period of around 4 days, 5 days, 6 days, 7 days, or 8 days.
- Any cell culture instrument can be used in the invention. These include, e.g., a petri dish, a flask, a bag, a bioreactor etc. can be used.
- a C0 2 gas permeable bag for cell culture can be used.
- use of a bioreactor is advantageous.
- the cell culturing can be performed in either an open system or a closed system, it is preferable to perform the culturing in a closed system from a view point of safety of the resulting M2 macrophages.
- M2 macrophages can be generated in vitro from monocytes or bone marrow cells with a library of antibodies as exemplified herein.
- the employed antibodies are single chain antibodies such as scFvs.
- the antibody library can be either an unbiased library of antibodies or a biased library of antibodies (e.g., CTSG biased antibodies).
- the cells e.g., CD34 + bone marrow cells
- the cells can be contacted with the antibodies by introducing vectors expressing the antibody library (e.g., lentiviral vectors) into the cells. After expressing the antibodies in the cells and culturing the cells under appropriate conditions, cells bearing M2 macrophage morphology and/or cellular markers can then be selected.
- Some related embodiments of the invention are directed to identifying antibodies (e.g., intact immunoglobulin molecules or scFvs) from a library containing antibody variable fragments that alters the morphology and function of bone marrow cells (e.g., CD34 + bone marrow cells).
- the selected M2 macrophages are further manipulated to isolate the specific antibody expressed therein.
- these novel M2-inducing antibody agents can be used in various therapeutic applications described herein.
- Detailed methods for introducing antibody-expressing vectors or viruses into monocytes or bone marrow cells and for selecting M2 macrophages can be based on routinely practiced protocols and the specific procedures exemplified herein.
- the invention provides methods and compositions for treating autoimmune diseases and other diseases (e.g., some inflammatory disorders) via the use of agonist antibodies described herein to induce formation of M2 microphages.
- autoimmune diseases and other diseases e.g., some inflammatory disorders
- treatment with the LKAb antibody resulted in therapeutic effects in subjects afflicted with systemic autoimmunity such as lupus (see, e.g., Example 6).
- systemic autoimmunity such as lupus
- the ability to induce a population of monocytes or monocyte precursors (e.g., from bone marrow cells) to become M2 macrophages enables production of anti-inflammatory cytokines that are beneficial for therapeutic applications.
- some embodiments of the invention provide pharmaceutical compositions containing a M2-inducing agonist antibody or a population of in vitro induced M2 macrophage as described herein. These pharmaceutical compositions are suitable for administration to patients so that the converted M2 macrophages can recognize and kill the neighboring diseased cells.
- a recognition element such as an antibody can be expressed on the M2 macrophage surface to provide more specific and/or stronger cytotoxicity against target cells.
- M2 macrophage populations induced with the agonist antibody and further enriched in vitro can be administered to subjects suffering from autoimmune diseases or other conditions with undesired immune responses.
- the pharmaceutical composition of the invention can be used alone or in combination with other known agents in the art for treating autoimmune diseases or other inflammatory disorders.
- compositions containing the M2 macrophage-inducing antibodies described herein or containing M2 macrophages produced by the method of the present invention may be used for treatment of various autoimmune diseases, inflammatory disorders and other conditions with undesired immune responses.
- diseases or conditions include, e.g., asthma, autoimmune diseases, chronic inflammation, chronic prostatitis, gomerulonephritis, hypersensitivities, inflammatory bowel diseases, pelvic inflammatory diseases, reperfusion injury, rheumatoid arthritis, transplant rejection and vasculitis.
- inflammatory disorders include, but are not limited to, rheumatoid arthritis, systemic lupus erythematosus, acute respiratory distress syndrome (ARDS), alopecia areata, anklosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome (alps), autoimmune
- thrombocytopenic purpura ATP
- Blehcet's disease bullous pemphigoid
- cardiomyopathy celiac sprue-dermatitis
- chronic fatigue syndrome immune deficiency syndrome (CFIDS)
- chronic inflammatory demyelinating polyneuropathy cicatricial pemphigoid
- cold agglutinin disease Crest syndrome, Crohn's disease
- Dego's disease dermatomyositis
- the therapeutic methods of the invention typically involve administering to a subject a pharmaceutical composition that contains an M2-inducing agonist antibody described herein or a population of M2 macrophages.
- the subject is a human patient.
- the agonist antibody is contacted with monocytes or precursor cells in vivo upon being administered to the subject to induce formation of M2 macrophage.
- a therapeutically effective amount of the antibody can be administered to a subject afflicted with an autoimmune disease or other inflammatory disorder.
- M2 macrophages can be induced which in turn can exert antiinflammatory activities.
- the antibody can be conjugated to a moiety that specifically recognizes a surface marker on the monocytes or monocytes precursors to facilitate targeted delivery of the agonist antibody, e.g., a ligand for a monocyte specific surface marker that is well known in the art (e.g., CD14).
- a bispecific antibody comprised of the antigen-binding site of the agonist antibody and also the antigen- binding site of a second antibody recognizing a monocyte specific surface marker can be used.
- Such immune conjugates or bispecific antibodies can be generated using standard procedures routinely practiced in the art.
- subjects with autoimmune diseases or other undesired immune responses can be treated ex vivo.
- the pharmaceutical composition to be administered to a subject contains a population of M2 macrophages generated in vitro via the methods described herein.
- a bone marrow sample or a population of monocytes can be first obtained from the subject in need of treatment.
- the cells are then contacted in vitro with a M2-inducing antibody described herein.
- the induced M2 macrophages are then administered to the subject in a pharmaceutical composition.
- the bone marrow cells for inducing M2 macrophage formation with the agonist antibody are obtained from the same subject into whom the resulting M2 macrophage population will be administered.
- Some preferred embodiments of the invention are directed to treating human subjects afflicted with or suspected of having autoimmune disorders.
- autoimmune disorders and related diseases suitable for the methods of the invention include, e.g., Acute disseminated encephalomyelitis (ADEM), Addison's disease, Alopecia areata, Ankylosing spondylitis, Antiphospholipid antibody syndrome (APS), Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Bullous pemphigoid, Behcet's disease, Coeliac disease, Chagas disease, Chronic obstructive pulmonary disease, Crohn's Disease, Dermatomyositis, Diabetes mellitus type 1 ,
- GVHD Guillain-Barre syndrome
- GRS Guillain-Barre syndrome
- MS Hashimoto's disease
- Hidradenitis suppurativa Kawasaki disease
- Idiopathic thrombocytopenic purpura Interstitial cystitis
- Lupus erythematosus Mixed Connective Tissue Disease
- Morphea Multiple sclerosis
- MS Myasthenia gravis
- Narcolepsy Neuromyotonia, Pemphigus vulgaris, Pernicious anaemia, Psoriasis, Psoriatic Arthritis, Polymyositis, Primary biliary cirrhosis, Rheumatoid arthritis, Schizophrenia, Scleroderma, Sjogren's syndrome, Stiff person syndrome, Temporal arteritis (aka "giant cell arteritis"), Ulcerative Colitis, Vasculitis, Vitiligo, Microscopic polyangiitis, Glomerulonephritis, and Wegener
- M2 macrophage populations generated in vitro by the methods described herein and therapeutic applications of such M2 macrophage populations.
- the induced cell population is preferably enriched for M2 macrophages.
- M2 macrophages can be first isolated from the induced cell population noted above, and then further enriched in vitro before being administered to a subject in need of treatment of a disease or disorder (e.g., autoimmune diseases). Isolation and enrichment of M2 macrophages from the induced cell population can be readily carried out with methods well known in the art. For example, activated M2 macrophages can be isolated or selected for cells expressing M2 macrophage specific markers.
- Such markers expressed by human M2 macrophage include, e.g., CD36 (aka “SR”, scavenger receptor), MHCII, ARG-1 (arginase- 1 ), CD 14, CD 163, CD206, TGM2 (transglutaminase 2), DecoyR, IL-1R II, CD86, VEGF, TLR1 and TLR8.
- Enrichment can also include staining cells from the induced cell population or previously selected cells with antibodies recognizing M2 macrophage specific markers (e.g., CD36 and ARG-1), and selecting for cells with high expression of Ml macrophage specific markers (e.g., ARG-1) and low expression of markers for other type of cells (e.g., Ml macrophage markers such as IDO-1).
- M2 macrophages can also be isolated or enriched by removal of cells other than M2 macrophages in the induced cell population.
- human M2 macrophages may be isolated or enriched by depletion of cells displaying non-M2 macrophage markers using, e.g., antibodies targeting such markers.
- markers include, e.g., CD1 lb, CD80, CD86, CD16/32, IL-1R I, TLR2, TLR4 and iNOS. Protocols reported in the literature can also be used and modified for isolation and enrichment of M2 macrophages in the methods of the present invention. See, e.g., Gabrilovich et al, Nat. Rev. Immunol. 12, 253-268, 2012, Kitani et al, Immonol. 4, 1 -7, 2014; and Yang et al, Mol. Endocrinol. 28:565-574, 2014.
- M2 macrophage populations of the invention typically contain at least 50%, 60%, 70%, 80%, 90%, 92%, 94%, 96%, 98% or more of homogeneous or
- heterogeneous M2 macrophages that express one or more of the specific M2 markers described herein.
- kits or pharmaceutical combinations for converting bone marrow cells or monocyte cells into M2 macrophages.
- the kits typically contain one or more agonist antibodies described herein, tools and materials for isolating bone marrow cells or monocyte populations from a subject, and reagents for co-culturing monocytes or precursor cells with the agonist antibody.
- the kits can contain the agonist antibody and a cultured monocyte cell population for generating M2 macrophages that can be applied allogeneically to subjects afflicted with autoimmune diseases or other inflammatory disorders.
- compositions containing an agonist antibody or a M2 macrophage population described herein can be administered to subjects in need of treatment in accordance with standard procedures of pharmacology.
- Methods of administering the therapeutic compositions to a subject can be accomplished based on procedures routinely practiced in the art. See, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Co, 20 th ed, 2000; Ritter et al, J. Clin. Invest. 1 16:3266-76, 2006; Iwasaki et al. Jpn. J. Cancer Res. 88:861-6, 1997; Jespersen et al., Eur. Heart J.
- a composition containing the induced M2 macrophages are typically administered (e.g., via injection) in a physiologically tolerable medium, such as phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- the isolated cells, or their engineered form as disclosed herein, should be administered to the subject in a number sufficient to inhibit the development of the disease in the subject.
- administration of therapeutic composition is carried out by local or central injection of the cells into the subject.
- the administration is via a systemic route such as peripheral administration. Additional guidance for preparation and administration of the pharmaceutical compositions of the invention are described in the art.
- Example 1 Selection system for identifying M2 macrophage-inducing antibodies
- Fig. 1A The unbiased antibody library in lentiviruses, which contains about 10 s unique members, was used to infect total mouse bone marrow cells. The infected cells were plated onto soft agar to observe the formation of colonies (Fig. IB). Large colonies were harvested, and the morphology of the cells therein was determined. All colonies contained cells with the classical morphology of macrophages (Fig. 1C, D). The antibody gene integrated into the cells was recovered by PCR. One sequence was repeated in 7 colonies and this antibody was chosen for further studies.
- This antibody gene was reinserted into lentivirus and fresh cells were infected. These cells, now infected with a single lentivirus, also formed colonies (Fig. I E) and contained cells with a morphology that was similar to those selected after the first round of infection.
- Fig. I E colonies
- Fig. I E the encoding gene was transferred to a mammalian expression vector.
- the purified antibody was incubated with bone marrow, a large percentage of the cells attached to the plate and developed a macrophage morphology (Fig. IF).
- LKAb antibody was incubated with an extract of total mouse bone marrow cells and the immune complexes were captured on a protein A/G column. Proteins that reacted with the antibody were identified by silver staining of SDS gels and their identity determined by mass spectrometry (Fig. 7A, B). Four candidate proteins based on the number of peptide "hits" were tested for their ability to bind to antibody LKAb (Fig. 7C). Out of the candidate antigens, only Cathepsin G (CTSG) bound to LKAb as determined by Western blotting and ELISA analyses (data not shown).
- CTSG Cathepsin G
- CTSG is known to be secreted by activated leukocytes, but it has also been shown to be present on the surface of monocytic cells.
- CTSG was confirmed as the target antigen by comparing LKAb to a commercial anti-CTSG antibody using Western blotting of an extract from cells over- expressing CTSG (Fig. 2A).
- the commercial anti-CTSG antibody also reacted strongly with a protein from mouse bone marrow extracts that was first captured by our antibody (Fig. 2B).
- the protein fraction captured by our antibody was shown to have CTSG activity (Fig. 2C).
- Fig. 2D the ability of our antibody to induce macrophage formation was markedly reduced.
- cytokine IL-10 is another feature of M2 macrophages.
- LKAb i.p. into C57BL/6 and BALB/c mice and found significantly higher levels of IL-10 in treated compared to control mice (Fig. 3E).
- cell lysates were assessed by Western blotting using anti-phospho p38, ERK and AKT. ERK and AKT were activated to some extent, but p38 was strongly activated, consistent with its known role in M2 macrophage polarization (Fig. 8).
- CTSG While CTSG is located on the surface of macrophages and polymorphonuclear leukocytes, it lacks a signal transduction domain, and thus its role in cell activation is indirect. Nevertheless, there is an increasing awareness of the role that CTSG plays in the regulation of important cell surface receptors. In particular, CTSG has been reported to regulate monocyte activation by down-regulation of CD 14, which is a critical co-receptor for TLR4 in the innate immune system and is involved in differentiation of cells in the macrophage lineage.
- TLR4 Since CD 14 and TLR4 are co-receptors, we studied whether TLR4 was also required for LKAb-mediated macrophage differentiation. Using bone marrow cells from wild-type and TLR4 (-/-) mice, we showed that the cell polarizing function of our antibody was TLR4-independent (Fig. 9). The finding that LKAb required CD 14 but not TLR4 to induce macrophage differentiation left open the question of the mechanism of signal transduction. Unlike TLR4, CD14 does not have a signal transduction domain. However, recently dendritic cells have been reported to be activated through a NFAT signaling pathway that is dependent on CD14 but independent of TLR4.
- NFAT knockout mice to determine whether this pathway plays a role in macrophage differentiation induced by our antibody.
- Bone marrow cells from NFATcl (-/-) and NFATc2 flox flox : CD4 Cre mice were incubated with LKAb and analyzed by FACS using the CD 14 and F4/80 markers.
- NFATcl (-/-) mice Fig. 4A.
- NFAT inactivation in non-macrophage cells such as CD4 expressing T cells and dendritic cells
- Fig. 4C we have a picture of CTSG's role in macrophage polarization suggesting that this molecule operates through CD 14 and NFAT to regulate macrophage activation and differentiation.
- Example 5 Inducing M2 macrophages from human bone marrow
- Mouse strains and cell lines The following mouse strains were used: C57BL/6J, BALB/c, C3H/HeJ, C3H/HeOuJ, C57BL/10ScNJ, B6.129S4-CD14 tm l fm /J and MRL/MPJ- Fas (lpr)/J (The Jackson laboratory).
- CTSG knockout mice were the generous gift of Dr. Christine Pham (Washington University, St. Louis, MO).
- NFATcl (-/-) and ⁇ 2 ⁇ / ⁇ : CD4 Cre mice were the generous gift of Dr. Anjana Rao (La Jolla institute for allergy and immunology).
- the F1EK293T cell line was maintained in DMEM medium containing 10% FCS, penicillin and streptomycin (Gibco-Invitrogen).
- the HEK293F cell line was maintained in Freestyle 293 Expression Media with 4 mM Glutamax (Gibco-Invitrogen).
- human total bone marrow cells All- Cells were cultured in StemSpan serum-free media with cytokine cocktail (STEMCELL Technologies) and the antibody (10 ⁇ g/ml) at 37°C.
- mice were similarly cultured, except that the cells were in the DMEM/F12 medium containing 10% FCS, penicillin and streptomycin (Gibco-Invitrogen). Mice were housed and handled according to protocols approved by the Institutional Animal Care and Use Committee at The Scripps Research Institute.
- Combinatorial antibody library and lentivirus Single-Chain Fv (ScFv) genes were obtained from a naive human combinatorial antibody library (1 ⁇ 10 1 1 library diversity). ScFv genes were sub-cloned into a lentiviral vector. Lentivirus was produced in HEK293T cells by co-transfection of lentiviral vectors with the pCMVD8.91 and pVSVg viral packaging vectors at a ratio of 1 : 1 : 1. Supernatants containing virus were collected at 48 h post-transfection. Cell debris was removed by centrifugation and filtration through a 0.22- ⁇ polyethersulfone membrane filter unit from Millipore. The titer of the lentivirus preparation was determined using a Lenti-X p24 ELISA (Clontech). The virus preparations were aliquoted and frozen at -80 °C.
- Transduction and colony forming cell assay The bone marrow cells were incubated with lentivirus for 3 days at 37 °C. Selection of agonist antibodies was done by a Colony-Forming Cell Assay using Methylcellulose-Based Media. Bone marrow cells were transduced with the lentiviral antibody library at a multiplicity of infection of 2 and added to methylcellulose media at the final concentrations of 1.27% methylcellulose and ⁇ 3 ⁇ 10 4 cells/mL. A total of 1.5 mL of cell suspension was added to 35-mm-diameter dishes. The cells in soft agar were cultured for 2 wk. The colonies were harvested with the aid of a micromanipulator (Sutter Instruments). The antibody genes from each colony were amplified by PCR with primer pairs customized for our lentiviral vector. The amplified antibody genes were analyzed by electrophoresis and recovered.
- the antibody expression vector was transfected into HEK293F cells. Antibodies from the pooled supernatants were purified using HiTrap Protein G HP columns with an AKTAxpress purifier (GE). The buffer was exchanged to Dulbecco's PBS (pH 7.4) and stored at 4 °C. The vector encoding the ScFv-Fc tag fusion protein was transfected into HEK293F cells for transient expression.
- Immunoprecipitation and Mass Spectrometry For immunoprecipitation, mouse bone marrow cells were prepared and solubilized in lysis buffer. The lysates were incubated with LKAb for 2 hours at 4°C, followed by incubation with 50 ⁇ of protein G-Sepharose beads (Pierce). The eluent was introduced into the linear trap quadrupole mass spectrometer from a nano-ion source with a 2-kV electrospray voltage. The analysis method consisted of a full MS scan with a range of 400-2,000 m/z followed by data-dependent MS/MS on the three most intense ions from the full MS scan. The raw data from the linear trap quadrupole were searched using the IPI human FASTA database with the MASCOT
- Silencing CTSG mRNA Mouse CTSG shRNAs (Santa Cruz Biotechnology) used for producing lentiviral particles contain three target-specific constructs designed to knock down gene expression. Mouse bone marrow cells were infected with Lentivirus CTSG shRNA and cultured with LKAb or M-CSF for 6 days.
- CD200R (BD Biosciences). Stained cells were analyzed with a LSRII flow cytometer (Becton Dickinson). To obtain CD1 lb positive and negative bone marrow cells, CD1 lb +
- CTSG enzymatic activity To monitor enzyme activities, we used an assay based on Cathepsin G-mediated cleavage of a specific substrate and release of the dye group pNA (4-Nitroaniline). This assay was performed with mouse bone marrow lysates that were incubated with LKAb or CTSG inhibitor.
- Cytokine assay Cytokines were quantified in serum collected from individual mice using a mouse cytokine magnetic bead panel (EMD Millipore) according to
- MRL-Fas lpr mice were treated i.p. with LKAb (75 ⁇ g/mouse) two times per week. Treatments were initiated at 6 weeks of age and the experiment was terminated at 20 weeks of age. Total and anti-chromatin serum IgG subclasses were assessed by ELISA using 96-well plates coated with goat anti-mouse IgG (Jackson ImmunoResearch Laboratories) and mouse chromatin, respectively. Bound antibodies were detected using alkaline phosphatase-conjugated goat antibodies (Caltag Laboratories) to mouse IgG or IgG2a, the main autoantibody subclass in this model.
- Statistical analysis The data are expressed as the means ⁇ SE. Statistical analysis was performed using the Student t test or by one-way analysis of variance and the post hoc test. The groups were analyzed by unpaired two-tailed Student's t test. Survival was analyzed by Kaplan-Meier plot and log rank test. P values of ⁇ 0.05 were considered significant.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides specific anti-Cathepsin G antibodies that are capable of inducing formation of anti-inflammatory macrophage. The invention also provides methods for generating anti-inflammatory macrophages. The methods involve contacting bone marrow cells or monocytes with a Cathepsin G antibody described herein, and culturing the cell mixture under conditions to allow formation of M2 macrophage. Also provided in the invention are therapeutic methods of using a pharmaceutical composition containing a Cathepsin G antibody or induced M2 macrophage described herein for treating autoimmune diseases and other disorders associated with undesired immune responses.
Description
Antibodies for Generating Anti-Inflammatory Macrophage and
Related Uses
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The subject patent application claims the benefit of priority to U.S. Provisional Patent Application Number 62/218,785 (filed September 15, 2015). The full disclosure of the priority application is incorporated herein by reference in its entirety and for all purposes.
BACKGROUND OF THE INVENTION
[0002] The fundamental problem that the immune system has is that it must kill an offending organism or tumor with minimal damage to self. This is difficult because the target and surrounding tissue are, chemically speaking, essentially the same. Thus, we know of many tissue injuries that are the result of the "shrapnel" from an immunological attack - a kind of collateral damage. Nature has evolved at least three less than perfect solutions to the problem of protecting the integrity of the host during an immunological attack. The first is containment, the second is high specificity of the T cell- or antibody-mediated response, and the third is an elaborate system of checks and balances. Thus, macrophages engulf bacteria and contain them in vesicles into which highly toxic chemicals are pumped. On the cellular side, the system of checks and balances operates, for example, by balancing effector and regulatory T-cells and/or pro-inflammatory and anti-inflammatory macrophages. However, in a therapeutic setting, one or the other arm of an otherwise balanced system may need to be favored. Such control has become one of the major goals in immunology for the treatment of autoimmunity and cancer.
[0003] There is a need in the art for better means for upregulating anti-inflammatory macrophage and for suppressing undesired immune responses. The present invention is directed to this and other unmet needs.
SUMMARY OF THE INVENTION
[0004] In one aspect, the invention provides isolated or purified anti-Cathepsin G
(CTSG) antibodies. These antibodies have the same binding specificity as that of a reference
anti-CTSG antibody having (1) heavy chain CDRl, CDR2 and CDR3 sequences respectively shown in GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and (2) light chain CDRl, CDR2 and CDR3 sequences respectively shown in SGSIASNS (SEQ ID NO:7), EN , and QSYDSNFHWV (SEQ ID NO:8). Some of the antibodies contain heavy chain CDRl , CDR2 and CDR3 sequences that are substantially identical to GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6), respectively; and light chain CDRl , CDR2 and CDR3 sequences that are substantially identical to SGSIASNS (SEQ ID NO: 7), ENN, and
QSYDSNFHWV (SEQ ID NO:8), respectively. Some antibodies contain heavy chain CDRl, CDR2 and CDR3 sequences that are respectively identical to GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and light chain CDRl, CDR2 and CDR3 sequences that are respectively identical to SGSIASNS (SEQ ID NO:7), ENN, and QSYDSNFHWV (SEQ ID NO:8) (SEQ ID NO:8).
[0005] Some antibodies of the invention contain heavy chain and light chain variable region sequences that are substantially identical to SEQ ID NO:2 and SEQ ID NO:3, respectively. Some antibodies contain heavy chain and light chain variable region sequences that are at least 90% or 95% identical to SEQ ID NO:2 and SEQ ID NO:3, respectively. Some of the antibodies contain heavy chain and light chain variable region sequences show in SEQ ID NO:2 and SEQ ID NO:3, respectively. In some embodiments, the antibody is a scFv having an amino acid sequence that is substantially identical to SEQ ID NO: 1. Some of the scFvs have an amino acid sequence that is at least 90% or 95% identical to SEQ ID NO: 1. In one embodiment, the scFv has a sequence shown in SEQ ID NO: 1.
[0006] In another aspect, the invention provides methods for inducing formation of antiinflammatory M2 macrophages. The methods entail contacting a population of bone marrow cells or monocytes with an anti-Cathepsin G antibody under conditions sufficient to induce formation of anti-inflammatory macrophage, wherein the anti-Cathepsin G antibody has the same binding specificity as that of a reference antibody comprising (a) heavy chain CDRl, CDR2 and CDR3 sequences respectively shown in GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and (b) light chain CDRl , CDR2 and CDR3 sequences respectively shown in SGSIASNS (SEQ ID NO:7), ENN, and
QSYDSNFHWV (SEQ ID NO: 8). In some of these methods, the employed bone marrow cells are human bone marrow cells. In some methods, the contacting occurs in vitro by
culturing the population of bone marrow cells or monocytes in the presence of the anti- Cathepsin G antibody. In some embodiments, the cells are cultured with the antibody for about 4 to 20 days. Some of the methods further include isolating CD1 lb- cells from the cultured cell population. Some methods further include detecting in the cultured cell population at least one cellular marker expressed by M2 macrophage, e.g., CD36, MHCII, CD 14, or ARG-1. In some methods, contacting the cells with the antibody occurs in vivo in a subject. In some of these methods, the subject is afflicted with an autoimmune disease, and the antibody is administered to the subject via a pharmaceutical composition. Some methods of the invention use an anti-Cathepsin G antibody having an amino acid sequence that is substantially identical to SEQ ID NO: l . Some related embodiments of the invention provide populations of anti-inflammatory M2 macrophages produced by the methods of the invention.
[0007] In another aspect, the invention provides methods for treating or ameliorating the symptoms of an autoimmune disease in a subject. The methods involve administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an anti-Cathepsin G antibody. The anti-Cathepsin G antibody used in the methods typically has the same binding specificity as that of a reference antibody comprising (a) heavy chain CDRl, CDR2 and CDR3 sequences respectively shown in GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO: 5), and AREEEQQFSLDY (SEQ ID NO:6); and (b) light chain CDRl, CDR2 and CDR3 sequences respectively shown in SGSIASNS (SEQ ID NO:7), EN , and QSYDSNFHWV (SEQ ID NO: 8). Some of the methods are directed to treating lupus. In some embodiments, the employed antibody has heavy chain CDRl , CDR2 and CDR3 sequences that are respectively identical to GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and light chain CDRl , CDR2 and CDR3 sequences that are respectively identical to SGSIASNS (SEQ ID NO:7), ENN, and QSYDSNFHWV (SEQ ID NO:8) (SEQ ID NO:8). In some methods, the employed antibody has heavy chain and light chain variable region sequences show in SEQ ID NO:2 and SEQ ID NO:3, respectively. In some embodiments, the employed antibody is a scFv having an amino acid sequence that is substantially identical to SEQ ID NO: l . In one embodiment, the employed anti-Cathepsin G antibody is a scFv fragment shown in SEQ ID NO: l .
[0008] In still another aspect, the invention provides methods for obtaining antiinflammatory M2 macrophages from a population of bone marrow cells or monocytes. These methods entail (a) introducing into the bone marrow cells or monocytes a plurality of vectors expressing a library of antibodies, (b) culturing the cells harboring the vectors under conditions to express the library of antibodies, and (c) selecting one or more macrophages from the cells expressing the library of antibodies. In some embodiments, the library of antibodies are unbiased, e.g., unbiased scFv antibody library. In some other embodiments, the employed antibodies are biased, e.g., antibodies recognizing CTSG. In some methods, the antibodies are expressed from a lentiviral based vector. In some methods, the employed cells are CD34+ bone marrow cells. In some methods, selection of M2 macrophages is based on cell morphology. In some other methods, selection of M2 macrophages is based on expression of one or more M2 surface markers. Some methods of the invention further include isolating the antibody-expressing vectors from the selected M2 macrophages. These methods allow one to obtain novel M2 macrophage-inducing antibody agents that can be readily used in various therapeutic applications described herein, e.g., treating autoimmune diseases.
[0009] A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification and claims.
DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 shows selection of an agonist antibody that induces macrophage cell differentiation. (A) Scheme of the phenotype selection. The selection starts with a human scFv phage library (109 members). ScFv genes were transferred to a lentiviral vector to make lentiviral intra-body libraries. Total mouse bone marrow cells were infected with the antibody library and plated on soft agar. (B) After 2 weeks of incubation, 7 colonies with compact morphologies had grown. (C, D) These colonies were harvested and the antibody genes were recovered by PCR. One sequence was present in all colonies and was used for further studies. H&E staining of cells from the colonies showed cells with the classical morphologies of macrophages. (E) The experiment was repeated using the selected sequence incorporated into lentivirus. This antibody clone (identified as LKAb) again induced colonies with a similar morphology that contained cells with macrophage morphologies. (F)
After 1 week incubation with the purified LKAb antibody, bone marrow cells differentiated in culture to cells with morphologies consistent with that of macrophages.
[0011] Figure 2 shows identification of a novel antigen recognized by LKAb. (A) Both commercial anti-CTSG antibody and LKAb bound to a 28 kDa protein in Western blots of lysates from cells overexpressing CTSG. (B) Lysates of mouse bone marrow cells were incubated with LKAb for immuno-purification. Eluates from these immune complexes bound to the commercial anti-CTSG antibody in Western blots. (C) A CTSG enzymatic assay showed that CTSG enzyme activity was present in the eluates and mouse bone marrow total lysates. (D) Mouse bone marrow was incubated for two days with lentiviruses containing CTSG shRNA. This was followed by incubation with LKAb or M-CSF for 6 days. Cells were then stained with anti-CD 1 lb and anti-F4/80. FACS analysis showed that the induced macrophage populations were dramatically reduced when CTSG mRNA was silenced. However, M-CSF still induced macrophages when CTSG mRNA was silenced. The percentages of macrophages are shown (right). *P<0.05 (Student's t-test).
[0012] Figure 3 shows that LKAb induced anti-inflammatory M2 macrophage differentiation. (A) Mouse bone marrow cells were incubated with LKAb at the indicated concentrations (l-10(^g/ml) for 6 days. Cells were then stained with anti-CDl lb and anti- CD1 l c and analyzed by FACS. Encircled shapes identify positive macrophage populations. LKAb induces differentiation of CD1 lb+ macrophages but not CD1 lc+ dendritic cells. This process is dose dependent. (B) Mouse total bone marrow cells were separated using CD1 lb- specific magnetic beads, and the isolated CD 1 lb-positive or -negative populations were incubated with LKAb or M-CSF for 6 days. Cells were then stained with anti-CDl lb and anti-F4/80 and analyzed by FACS. Macrophage differentiation was mainly induced from the CD 1 lb-negative population. (C) Mouse bone marrow was incubated with medium, LKAb or M-CSF for 6 days. Cells were then stained with anti-CDl 6/32 and anti-CD86 as Ml macrophage markers, and anti-CD36, anti-MHCII and anti-CD 14 as M2 macrophage markers. Encircled shapes mark M2 type specific populations. The macrophages induced by LKAb selectively expressed M2 type markers. (D) Mouse bone marrow was induced by LKAb antibody or M-CSF for 6 days. Cells were harvested and total RNA was extracted for qRT-PCR analysis. IDOl was used as a Ml specific gene and Arg-1 as a M2 specific gene. qRT-PCR showed high Arg-1 mRNA expression in macrophages induced by LKAb but only low levels of IDOl . *** p<0.0005 (Student's t-test). (E) Macrophages induced by the LKAb
in vivo expressed M2 cytokines. LKAb and PBS were injected i.p. into C57BL/6 or BALB/c mice 3 times/week for 2 weeks and IL-10 levels in the sera were measured. Mice treated with LKAb showed dramatically increased IL-10 levels. IL-10 is one of the major antiinflammatory cytokines. *** p<0.0005 (Student's t-test).
[0013] Figure 4 shows that CTSG, CD14 and NAFAT play a key role in LKAb- dependent M2 macrophage differentiation. (A) Bone marrow cells from wild type, CTSG knockout, CD 14 knockout mice or NFAT knockout mice were incubated with medium, LKAb or M-CSF for 6 days. Cells were then stained with anti-CD 14 and anti-F4/80. FACS analysis showed CD14 and F4/80 expression was increased by LKAb in normal mice.
However, CD 14 and F4/80 expression was significantly reduced in both the CTSG and CD 14 knockout mice. CD 14 and F4/80 expression was also reduced in NFATcl, but not in NFATc2:CD4Cre, knockout mice. The percentages of M2 macrophages are shown (bottom). *P<0.05 (Student's t-test). (B) Wild type mouse bone marrow cells were incubated with LKAb, a CTSG inhibitor, or both, and CTSG activity was determined. The antibody-induced reduction of CTSG activity was comparable to that of the inhibitor. (C) Critical cell surface components and their downstream signaling pathways potentially involved in macrophage differentiation mediated by LKAb (pictured here as bound to CTSG).
[0014] Figure 5 shows that LKAb induces human bone marrow cells to differentiate into M2 macrophages. Human total bone marrow was incubated with medium, LKAb or M-CSF for 6 days. Cells were then stained with anti-CDl lb and anti-CD64 as Ml type markers, and anti-CD 14, anti-CD206 and anti-CD200R as M2 markers. Encircled shapes mark the M2 type specific populations. As with mice, LKAb also induced human bone marrow to differentiate into anti-inflammatory macrophages.
[0015] Figure 6 shows that treatment with LKAb reduced lupus-like disease in MRL-lpr mice. Mice (6-7/group) were injected i.p. with LKAb or PBS (from the age of 6 weeks until termination of the experiment at 20 weeks) and followed for manifestations of disease. (A) IgG2a anti-chromatin autoantibody levels determined by ELISA at 12 weeks of age. (B) Progression of lymphadenopathy between 12 and 16 weeks of age assessed by palpation of axillary and salivary lymph nodes (LNs) and scored on a 0-4 scale. (C) Kidney disease determined by histological examination for glomerulonephritis (GN) at 20 weeks of age. Representative images for treated and control mice are shown. (D) Kaplan-Meier plot representing survival rates of treated and control mice. Significant differences between
LKAb treated and PBS control mice are indicated by * p<0.05, ** p<0.005, *** p<0.0005 (Student's t-test).
[0016] Figure 7 shows LKAb's target identification by mass spectrometry. (A) Cell lysates of mouse bone marrow were incubated with LKAb for immunoprecipitation. Immuno-precipitated eluates were separated on SDS/PAGE gels that were silver-stained. (B, C) Nano-LC-MS/MS analysis identified several candidates as antigen.
[0017] Figure 8 shows LKAb activated signaling pathways. Mouse bone marrow cells were incubated with LKAb, M-CSF or GM-CSF and analyzed by Western blot with antibodies specific for phospho-AKT, ERK and p38.
[0018] Figure 9 shows that LKAb-induced macrophage differentiation requires CD 14 but not TLR4. Mouse bone marrow cells from C3H/HeOuJ (wild type), C3H/HeJ (TLR4 mutation) or C57BL/10ScNJ (TLR4 knockout) mice were incubated with LKAb, M-CSF or vehicle (C3H/HeOuJ only) for 6 days. Cells were then stained with anti-CD36 or anti- CD16/32. There is no macrophage differentiation in cells from CD14 (-/-) mice incubated with LKAb.
DETAILED DESCRIPTION OF THE INVENTION
I. Overview
[0019] The recent discovery of many agonist antibodies that govern cell fates has opened the way to induce selectively a large variety of specific cells of the immune system from normal or malignant bone marrow or blood. Often these agonist antibodies induce cell differentiation along lineages expected from the known function of the receptor to which they bind. In other cases, they activate differentiation or trans-differentiation pathways that are different from what would be expected from the nature of the receptor with which they interact.
[0020] The present invention is predicated in part on the studies undertaken by the present inventors to obtain antibody agonists that can selectively induce formation of antiinflammatory M2 macrophages. Specifically, as detailed in the Examples herein, the inventors used an unbiased intracellular combinatorial library of antibodies and identified an antibody (termed "LKAb" herein) that induces bone marrow cells to differentiate into M2 macrophages. The inventors also found that the primary target of the antibody is Cathepsin G (CTSG), and that LKAb inhibited CTSG activity by 50%. It was additionally observed
that the requirements for efficient macrophage polarization by this antibody include the presence of CTSG and CD 14 that appear to operate via p38, a classical marker for macrophage differentiation. The target is unusual in that CTSG was classically thought to be an effector molecule secreted by activated PMNs. Importantly, the antibodies identified by the inventors were found to be therapeutically effective in blocking autoimmunity in a classic mouse model of spontaneous systemic lupus erythematosus (SLE).
[0021] The exact role of CTSG in the unanticipated function of inducing antiinflammatory M2 macrophages is not yet fully understood. However, the observations by the inventors suggest that this effect is dependent on inhibition of CTSG proteolytic activity, upregulation of CD14, and activation of NFAT-dependent signaling. The efficacy of this antibody in reducing nephritis in a mouse model of lupus suggests that a similar treatment can be applicable to several inflammatory syndromes in which inflammatory macrophages frequently predominate and mediate tissue damage in afflicted organs.
[0022] In accordance with these studies, the present invention provides specific antibody agents that are capable of inducing formation of M2 macrophages from monocytes or bone marrow cells. The invention also provides methods for generating M2 macrophages from bone marrow cells with a library of unbiased antibodies, CTSG biased antibodies, or the specific anti-CTSG antibodies exemplified herein. The invention further provides methods of using the identified anti-CTSG antibodies and derivatives therefrom for treating autoimmunity and for suppressing undesired immune responses.
II. Definitions
[0023] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention pertains. The following references provide one of skill with a general definition of many of the terms used in this invention: Academic Press Dictionary of Science and
Technology, Morris (Ed.), Academic Press (1st ed., 1992); Oxford Dictionary of
Biochemistry and Molecular Biology, Smith et al. (Eds.), Oxford University Press (revised ed., 2000); Encyclopaedic Dictionary of Chemistry, Kumar (Ed.), Anmol Publications Pvt. Ltd. (2002); Dictionary of Microbiology and Molecular Biology, Singleton et al. (Eds.), John Wiley & Sons (3rd ed, 2002); Dictionary of Chemistry, Hunt (Ed.), Routledge (1st ed, 1999); Dictionary of Pharmaceutical Medicine, Nahler (Ed.), Springer-Verlag Telos (1994);
Dictionary of Organic Chemistry, Kumar and Anandand (Eds.), Anmol Publications Pvt. Ltd. (2002); and A Dictionary of Biology (Oxford Paperback Reference), Martin and Hine (Eds.), Oxford University Press (4th ed., 2000). In addition, the following definitions are provided to assist the reader in the practice of the invention.
[0024] The term "antibody" or "antigen-binding fragment" refers to polypeptide chain(s) which exhibit a strong monovalent, bivalent or polyvalent binding to a given antigen, epitope or epitopes. Unless otherwise noted, antibodies or antigen-binding fragments used in the invention can have sequences derived from any vertebrate, camelid, avian or pisces species. They can be generated using any suitable technology, e.g., hybridoma technology, ribosome display, phage display, gene shuffling libraries, semi-synthetic or fully synthetic libraries or combinations thereof. Unless otherwise noted, the term "antibody" as used in the present invention includes intact antibodies, antigen-binding polypeptide fragments and other designer antibodies that are described below or well known in the art (see, e.g., Serafini, J Nucl. Med. 34:533-6, 1993).
[0025] An intact "antibody" typically comprises at least two heavy (H) chains (about 50- 70 kD) and two light (L) chains (about 25 kD) inter-connected by disulfide bonds. The recognized immunoglobulin genes encoding antibody chains include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
[0026] Each heavy chain of an antibody is comprised of a heavy chain variable region (VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CHI , C H2 and C Η3· Each light chain is comprised of a light chain variable region (VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system and the first component (Clq) of the classical complement system.
[0027] The VH and VL regions of an antibody can be further subdivided into regions of hypervariability, also termed complementarity determining regions (CDRs), which are interspersed with the more conserved framework regions (FRs). Each VH and VL is
composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The locations of CDR and FR regions and a numbering system have been defined by, e.g., Kabat et ah, Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, U.S. Government Printing Office (1987 and 1991).
[0028] Antibodies to be used in the invention also include antibody fragments or antigen-binding fragments which contain the antigen-binding portions of an intact antibody that retain capacity to bind the cognate antigen. Examples of such antibody fragments include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an intact antibody; (v) disulfide stabilized Fvs (dsFvs) which have an interchain disulfide bond engineered between structurally conserved framework regions; (vi) a single domain antibody (dAb) which consists of a VH domain (see, e.g., Ward et al., Nature 341 :544-546, 1989); and (vii) an isolated complementarity determining region (CDR).
[0029] Antibodies suitable for practicing the present invention also encompass single chain antibodies. The term "single chain antibody" refers to a polypeptide comprising a VH domain and a VL domain in polypeptide linkage, generally linked via a spacer peptide, and which may comprise additional domains or amino acid sequences at the amino- and/or carboxyl-termini. For example, a single-chain antibody may comprise a tether segment for linking to the encoding polynucleotide. As an example, a single chain variable region fragment (scFv) is a single-chain antibody. Compared to the VL and VH domains of the Fv fragment which are coded for by separate genes, a scFv has the two domains joined (e.g., via recombinant methods) by a synthetic linker. This enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules.
[0030] Antibodies that can be used in the practice of the present invention also encompass single domain antigen-binding units which have a camelid scaffold. Animals in the camelid family include camels, llamas, and alpacas. Camelids produce functional antibodies devoid of light chains. The heavy chain variable (VH) domain folds
autonomously and functions independently as an antigen-binding unit. Its binding surface involves only three CDRs as compared to the six CDRs in classical antigen-binding
molecules (Fabs) or single chain variable fragments (scFvs). Camelid antibodies are capable of attaining binding affinities comparable to those of conventional antibodies.
[0031] The various antibodies or antigen-binding fragments described herein can be produced by enzymatic or chemical modification of the intact antibodies, or synthesized de novo using recombinant DNA methodologies, or identified using phage display libraries. Methods for generating these antibodies or antigen-binding molecules are all well known in the art. For example, single chain antibodies can be identified using phage display libraries or ribosome display libraries, gene shuffled libraries (see, e.g., McCafferty et al., Nature 348:552-554, 1990; and U.S. Pat. No. 4,946,778). In particular, scFv antibodies can be obtained using methods described in, e.g., Bird et al., Science 242:423-426, 1988; and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988. Fv antibody fragments can be generated as described in Skerra and Pluckthun, Science 240: 1038-41 , 1988. Disulfide- stabilized Fv fragments (dsFvs) can be made using methods described in, e.g., Reiter et al., Int. J. Cancer 67: 1 13-23, 1996. Similarly, single domain antibodies (dAbs) can be produced by a variety of methods described in, e.g., Ward et al., Nature 341 :544-546, 1989; and Cai and Garen, Proc. Natl. Acad. Sci. USA 93:6280-85, 1996. Camelid single domain antibodies can be produced using methods well known in the art, e.g., Dumoulin et al., Nature Struct. Biol. 1 1 :500-515, 2002; Ghahroudi et al., FEBS Letters 414:521-526, 1997; and Bond et al., J Mol Biol. 332:643-55, 2003. Other types of antigen-binding fragments (e.g., Fab, F(ab')2 or Fd fragments) can also be readily produced with routinely practiced immunology methods. See, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1998.
[0032] The term "contacting" has its normal meaning and refers to combining two or more agents (e.g., polypeptides or phage), combining agents and cells, or combining two populations of different cells. Contacting can occur in vitro, e.g., mixing two polypeptides or mixing a population of antibodies with a population of cells in a test tube or growth medium. Contacting can also occur in a cell or in situ, e.g., contacting two polypeptides in a cell by coexpression in the cell of recombinant polynucleotides encoding the two
polypeptides, or in a cell lysate. Contacting can also occur in vivo inside a subject, e.g., via targeted delivery of an antibody to a specific group of cells.
[0033] The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the
same. Two sequences are "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length.
[0034] Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 2:482c, 1970; by the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443, 1970; by the search for similarity method of Pearson and Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444, 1988; by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, WI); or by manual alignment and visual inspection (see, e.g., Brent et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (ringbou ed., 2003)). Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402, 1977; and Altschul et al., J. Mol. Biol. 215:403-410, 1990, respectively.
[0035] A "ligand" is a molecule that is recognized by a particular antigen, receptor or target molecule. Examples of ligands that can be employed in the practice of the present invention include, but are not restricted to, agonists and antagonists for cell membrane receptors, toxins and venoms, viral epitopes, hormones, hormone receptors, polypeptides, peptides, enzymes, enzyme substrates, cofactors, drugs (e.g. opiates, steroids, etc.), lectins, sugars, polynucleotides, nucleic acids, oligosaccharides, proteins, and monoclonal antibodies. In some embodiments, the ligand is a molecule that specifically binds to a monocyte surface marker.
[0036] M2 macrophages (also termed "alternatively activated macrophages" or "antiinflammatory macrophages") are one of two main groups of macrophages. The other group
of macrophages, M l macrophages (or "classically activated macrophages"), are "killer" macrophages which are activated by LPS and IFN-gamma, and secrete high levels of IL-12 and low levels of IL-10. In contrast, M2 macrophages function in constructive processes like wound healing and tissue repair, and turn off damaging immune system activation by producing anti-inflammatory cytokines. M2 is the phenotype of resident tissue
macrophages, and can be further elevated by IL-4. M2 macrophages produce high levels of IL-10, TGF-beta and low levels of IL-12. The names Ml and M2 were chosen because Ml and M2 macrophages promote Thl and Th2 responses, respectively. Products of Thl and Th2 responses (e.g., IFN-γ, IL-4) also down regulate M2 and Ml activity, respectively.
[0037] Monocytes are a type of leukocytes (white blood cells) and are part of the innate immune system of vertebrates including all mammals. Monocytes constitute 2% to 10% of all leukocytes in the human body. They constitute between three to eight percent of the leukocytes in the blood. Half of them are stored as a reserve in the spleen. Monocytes play multiple roles in immune function. Such roles include: (1) replenishing resident
macrophages under normal states, and (2) in response to inflammation signals. Monocytes can move quickly (approx. 8-12 hours) to sites of infection in the tissues and
divide/differentiate into macrophages and dendritic cells to elicit an immune response. Monocytes are produced by the bone marrow from precursors called monoblasts, bipotent cells that differentiated from hematopoietic stem cells. Monocytes circulate in the bloodstream for about one to three days and then typically move into tissues throughout the body.
[0038] Unless otherwise noted, the term "receptor" broadly refers to a molecule that has an affinity for a given ligand. Receptors may-be naturally-occurring or manmade molecules. Also, they can be employed in their unaltered state or as aggregates with other species. Receptors may be attached, covalently or noncovalently, to a binding member, either directly or via a specific binding substance. A typical example of receptors which can be employed in the practice of the invention is cell surface receptor.
[0039] The term "subject" refers to human and non-human animals (especially non- human mammals). In addition to human, it also encompasses other non-human animals such as cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys.
[0040] The term "target," "target molecule," or "target cell" refers to a molecule or biological cell of interest that is to be analyzed or detected, e.g., a ligand such as a cytokine or hormone, a polypeptide, a cellular receptor or a cell.
[0041] A cell has been "transformed" by exogenous or heterologous polynucleotide when such polynucleotide has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming polynucleotide may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming polynucleotide has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming polynucleotide. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth in vitro for many generations.
III. Antibodies converting bone marrow cells into M2 microphages
[0042] The invention provides novel M2 macrophage-inducing antibodies that can convert bone marrow cells (e.g., CD34+ cells) or monocytes into anti-inflammatory macrophage. These agonist antibodies have the same binding specificity as that of a specific anti-CTSG scFv antibody ("LKAb") identified herein. As exemplified herein, antibody LKAb can induce M2 macrophage formation from both human and mouse bone marrow cells (see, e.g., Figs. 3 and 5). This scFv antibody has an amino acid sequence shown in SEQ ID NO: 1. The sequences of the heavy chain and the light chain portions of the scFv are respectively shown in SEQ ID NOs:2 and 3. The CDR sequences of the heavy chain variable region of this antibody are GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQF SLD Y (SEQ ID NO:6). The CDR sequences of its light chain variable region are SGSIASNS (SEQ ID NO:7), ENN, and QSYDSNFHWV (SEQ ID NO:8).
[0043] The antibodies of the invention for inducing M2 macrophage are preferably monoclonal antibodies like the antibodies exemplified in the Examples below. In general, the antibodies have the same binding specificity as that of the LKAb agonist antibody and
compete with the LKAb antibody for binding to Cathepsin G. In addition to containing variable regions sequences derived from the LKAb antibody, some agonist antibodies of the invention can also contain other antibody sequences fused to the variable region sequences. For example, the antibodies can contain an Fc portion of IgG. The antibodies can also be conjugated, covalently or noncovalently, to another entity that specifically targets a surface antigen, receptor or marker on monocyte cells.
[0044] Some M2 macrophage-inducing agonist antibodies of the invention harbor variable region sequences that are substantially identical (e.g., at least 90% or 95% identical) to that of the LKAb antibody. Some other agonist antibodies have all CDR sequences in their variable regions of the heavy chain and light chain that are respectively identical or substantially identical (e.g., at least 90% or 95% identical) to the corresponding CDR sequences of the LKAb agonist antibody. In still some other embodiments, the agonist antibody has its entire heavy chain and light chain variable region sequences respectively identical to the corresponding variable region sequences of the LKAb antibody. In some other embodiments, other than the identical CDR sequences, the antibodies contain amino acid residues in the framework portions of the variable regions that are different from the corresponding amino acid residues of the LKAb antibody. Relative to the LKAb antibody, the agonist antibodies of the invention can undergo non-critical amino-acid substitutions, additions or deletions in the variable region without loss of binding specificity or effector functions, or other modifications that do not cause intolerable reduction of binding affinity or CTSG-inhibiting activities. Usually, antibodies incorporating such alterations exhibit substantial sequence identity to the LKAb antibody. For example, the mature light chain variable regions of some of the agonist antibodies of the invention have at least 75%, at least 85% or at least 90% sequence identity to the sequence of the mature light chain variable region of the LKAb antibody. Similarly, the mature heavy chain variable regions of the antibodies typically show at least 75%, at least 85% or at least 90% sequence identity to the sequence of the mature heavy chain variable region of the LKAb antibody. In various embodiments, the antibodies typically have their entire variable region sequences that are substantial identical (e.g., at least 75%, 85%, 90%, 95%, or 99%) to the corresponding variable region sequences of the LKAb antibody. Some M2 macrophage-inducing agonist antibodies of the invention have the same binding specificity but improved affinity or CTSG-inhibiting activities if compared with the LKAb antibody.
[0045] The agonist antibodies of the invention can be generated in accordance with routinely practiced immunology methods. Some of such methods are exemplified herein in the Examples. General methods for preparation of monoclonal or polyclonal antibodies are well known in the art. See, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1998; Kohler & Milstein, Nature 256:495-497, 1975; Kozbor et al., Immunology Today 4:72, 1983; and Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy, 1985.
IV. Converting monocytes or bone marrow cells into M2 macrophages
[0046] The invention provides methods for generating M2 macrophages as well as therapeutic applications of M2 macrophages generated in vitro or in vitro. In some embodiments, M2 macrophages are generated from monocytes or bone marrow cells (e.g., CD34+ cells) with a specific M2 macrophage-inducing antibody. Any of the agonist antibodies described herein can be used in the therapeutic methods of the invention for generating M2 macrophages in vivo or in vitro. M2 macrophages can be further divided into subsets M2a, M2b, and M2c based on gene expression profiles (Mantovani et al., Trends Immunol. 25:677-86, 2004). The M2a subtype is elicited by IL-4 or IL-13 (common IL-4R- alpha, CD124). The M2b is elicited by IL-1R ligands or exposure to immune complexes plus LPS. The M2c subtype can be elicited by IL-10, TGF-beta and glucocorticoid hormones. The fourth type of macrophage M2d is characterized by an IL-l Ohigh, IL-121ow M2 profile with some features of tumor-associated macrophages (TAMs). The M2d subtype has phenotypic and functional attributes similar to ovarian TAMs but distinct from M2a-c. The M2 macrophages produced by methods of the invention can include one or more of the subsets of M2 macrophages.
[0047] Typically, the methods involve contacting a M2 macrophage-inducing antibody described herein with a population of monocytes or monocyte precursor cells (e.g., bone marrow cells) isolated from a subject under appropriate conditions as exemplified herein to facilitate the conversion. The monocyte-containing samples can be maintained and cultured in any physiologically-acceptable solution suitable for the collection and/or culture of the cells. For example, human bone marrow cells can be cultured in StemSpan serum-free media (STEMCELL Technologies) as exemplified herein. Other suitable culture media include, e.g., a saline solution (e.g., phosphate-buffered saline, Kreb's solution, modified
Kreb's solution, Eagle's solution, 0.9% NaCl, etc.), and a culture medium (e.g., DMEM, H.DMEM, etc.), and the like. The solution can contain one or more tissue-degrading enzymes, e.g., a metalloprotease, a serine protease, a neutral protease, a hyaluronidase, an RNase, or a DNase, or the like. Such enzymes include, but are not limited to, collagenases (e.g., collagenase I, II, III or IV, a collagenase from Clostridium histolyticum, etc.); dispase, thermolysin, elastase, trypsin, LIBERASE, hyaluronidase, and the like. The solution can further include a bacteriocidal ly or bacteriostatically effective amount of an antibiotic.
Examples of suitable antibiotics include a macrolide (e.g., tobramycin), a cephalosporin (e.g., cephalexin, cephradine, cefuroxime, cefprozil, cefaclor, cefixime or cefadroxil), a clarithromycin, an erythromycin, a penicillin (e.g., penicillin V) or a quinolone (e.g., ofloxacin, ciprofloxacin or norfloxacin), a tetracycline, a streptomycin, and etc.
[0048] In some embodiments, the isolated or cultured monocyte or precursor cells can also be contacted with another agent that promotes monocyte differentiation into M2 macrophage. For example, the population of monocytes or precursors can be stimulated with the cytokines noted above for eliciting different M2 subtypes (e.g., IL-4 or IL-10). A cytokine cocktail for inducing M2 macrophage from human bone marrow cells is exemplified herein. The cells can also be stimulated with macrophage colony stimulating factor (M-CSF). M-CSF has been shown to polarize monocytes towards M2 macrophages (Jaguin et al., Cell Immunol. 281 :51-61, 2013). In various embodiments, contacting the monocyte cell population with the stimulating cytokine such as M-CSF can be performed prior to, simultaneously with or subsequent to treatment with the antibody. The
concentration of each of the cytokines or agents in the culture medium can be in the range of, e.g., about 0.01 to 1 x 10s U/ml. The culture medium can further contain serum or plasma. The amount of serum or plasma can be present at concentration of, e.g., about 0 to 20% by volume, preferably more than 0 to 10% by volume.
[0049] The in vitro induced M2 macrophage population can be further subject to analysis for expression of M2 markers and enrichment for M2 macrophages. For example, the cells can be examined for expression of "anti-inflammatory" cytokine expression profile, which includes high levels of IL-10 and IL-1RA and low expression of IL-12. M2 macrophages also express high levels of scavenger mannose and galactose receptors. The cells can also be examined for cytokine profiles indicative of the different subtypes of M2 macrophages. For example, M2a macrophages produce IL-10, TGFp and IL-lra, M2b
macrophages produce IL-1 , IL-6, IL-10 and TGFa, M2c macrophages produce IL-10 and TGFp, and M2d macrophages produce IL-10, IL-12, TNFa and TNFp. Moreover, M2 macrophages also have distinct chemokine and chemokine receptor profiles unlike that of Ml macrophages. For example, M2 macrophages expresses chemokines CCL17, CCL22 and CCL24 while Ml macrophages secret the TH1 cell-attracting chemokines CXCL9 and CXCL10.
[0050] The culture of a cell population in the presence of the agonist antibody and/or other agents can be performed in accordance with standard cell culturing protocols well known in the art. Some specific procedures for generating M2 macrophages from bone marrow cells are exemplified herein. Typically, the isolated bone marrow cells or monocyte population are contacted with an effective amount of an antibody having the same binding specificity as that of LKAb agonist antibody under appropriate conditions to facilitate the conversion. In some embodiments, the antibody is contacted with the cells in vitro. In these embodiments, the cell population can be cultured at a concentration of about lxl O2, lxlO3, lxl O4, lxlO5, lxlO6, lxlO7, lxlO8 cells/ml or higher. As exemplified herein, the bone marrow cells or monocytes can be cultured in the presence of an effective amount of the antibody, e.g., at a concentration of 0.1 , 0.25, 0.5, 1.0, 2.5, 5.0, 10, 25, 50, 100 μg/ml or higher. The contacting can last for a sufficient period of time, e.g., at least 12 hours, 1 day, 2 days, 4 days, 6 days, 10 days, 25 days, 50 days, 75 days, 100 days or longer. In some of these embodiments, the cells can be examined along the process for molecular markers and/or morphology indicative of the presence of M2 macrophages as exemplified herein.
[0051] The cell culture may be performed under known culture conditions, and the conditions which are used in normal cell culture can be applied. For example, culture can be performed under the conditions of 37°C and 5% C02. Cells can be diluted by adding a fresh medium to a cell culture liquid at a suitable time interval, a medium can be exchanged with a fresh medium, or a cell culture instrument can be exchanged. In some embodiments, the culturing period for converting the bone marrow cells into M2 macrophages can be, e.g., from 1 to 100 days, 2 to 75 days, 3-50 days, or 4-25 days. In some embodiments, the bone marrow cells are cultured in the presence of the agonist antibody and other agents for a period of around 4 days, 5 days, 6 days, 7 days, or 8 days. Any cell culture instrument can be used in the invention. These include, e.g., a petri dish, a flask, a bag, a bioreactor etc. can be used. For cell culture bags, a C02 gas permeable bag for cell culture can be used. When
a large amount of cells are being treated, use of a bioreactor is advantageous. Although the cell culturing can be performed in either an open system or a closed system, it is preferable to perform the culturing in a closed system from a view point of safety of the resulting M2 macrophages.
[0052] In some embodiments, M2 macrophages can be generated in vitro from monocytes or bone marrow cells with a library of antibodies as exemplified herein. In some embodiments, the employed antibodies are single chain antibodies such as scFvs. The antibody library can be either an unbiased library of antibodies or a biased library of antibodies (e.g., CTSG biased antibodies). In these methods, the cells (e.g., CD34+ bone marrow cells) can be contacted with the antibodies by introducing vectors expressing the antibody library (e.g., lentiviral vectors) into the cells. After expressing the antibodies in the cells and culturing the cells under appropriate conditions, cells bearing M2 macrophage morphology and/or cellular markers can then be selected. Some related embodiments of the invention are directed to identifying antibodies (e.g., intact immunoglobulin molecules or scFvs) from a library containing antibody variable fragments that alters the morphology and function of bone marrow cells (e.g., CD34+ bone marrow cells). In these embodiments, the selected M2 macrophages are further manipulated to isolate the specific antibody expressed therein. By driving monocytic cells to become M2 macrophages, these novel M2-inducing antibody agents can be used in various therapeutic applications described herein. Detailed methods for introducing antibody-expressing vectors or viruses into monocytes or bone marrow cells and for selecting M2 macrophages can be based on routinely practiced protocols and the specific procedures exemplified herein.
V. Therapeutic applications
[0053] The invention provides methods and compositions for treating autoimmune diseases and other diseases (e.g., some inflammatory disorders) via the use of agonist antibodies described herein to induce formation of M2 microphages. As exemplified herein, treatment with the LKAb antibody resulted in therapeutic effects in subjects afflicted with systemic autoimmunity such as lupus (see, e.g., Example 6). The ability to induce a population of monocytes or monocyte precursors (e.g., from bone marrow cells) to become M2 macrophages enables production of anti-inflammatory cytokines that are beneficial for therapeutic applications. Accordingly, some embodiments of the invention provide
pharmaceutical compositions containing a M2-inducing agonist antibody or a population of in vitro induced M2 macrophage as described herein. These pharmaceutical compositions are suitable for administration to patients so that the converted M2 macrophages can recognize and kill the neighboring diseased cells. In some of these embodiments, a recognition element such as an antibody can be expressed on the M2 macrophage surface to provide more specific and/or stronger cytotoxicity against target cells. In some other embodiments, M2 macrophage populations induced with the agonist antibody and further enriched in vitro can be administered to subjects suffering from autoimmune diseases or other conditions with undesired immune responses. The pharmaceutical composition of the invention can be used alone or in combination with other known agents in the art for treating autoimmune diseases or other inflammatory disorders.
[0054] Pharmaceutical compositions containing the M2 macrophage-inducing antibodies described herein or containing M2 macrophages produced by the method of the present invention may be used for treatment of various autoimmune diseases, inflammatory disorders and other conditions with undesired immune responses. Such diseases or conditions include, e.g., asthma, autoimmune diseases, chronic inflammation, chronic prostatitis, gomerulonephritis, hypersensitivities, inflammatory bowel diseases, pelvic inflammatory diseases, reperfusion injury, rheumatoid arthritis, transplant rejection and vasculitis. Examples of specific inflammatory disorders include, but are not limited to, rheumatoid arthritis, systemic lupus erythematosus, acute respiratory distress syndrome (ARDS), alopecia areata, anklosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome (alps), autoimmune
thrombocytopenic purpura (ATP), Blehcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue syndrome immune deficiency, syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, cicatricial pemphigoid, cold agglutinin disease, Crest syndrome, Crohn's disease, Dego's disease, dermatomyositis,
dermatomyositis-juvenile, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia- fibromyositis, grave's disease, guillain-barre, hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA nephropathy, insulin dependent diabetes (Type 1), juvenile arthritis, Meniere's disease, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis
nodosa, polychondritis, polyglancular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, sarcoidosis, scleroderma, sepsis, Sjogren's syndrome, stiff-man syndrome, systemic inflammatory response syndrome (SIRS), Takayasu arteritis, temporal arteritis/giant cell arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo, and Wegener's granulomatosis.
[0055] The therapeutic methods of the invention typically involve administering to a subject a pharmaceutical composition that contains an M2-inducing agonist antibody described herein or a population of M2 macrophages. In some preferred embodiments, the subject is a human patient. In some embodiments, the agonist antibody is contacted with monocytes or precursor cells in vivo upon being administered to the subject to induce formation of M2 macrophage. For example, a therapeutically effective amount of the antibody can be administered to a subject afflicted with an autoimmune disease or other inflammatory disorder. Upon contacting the antibody with monocytes or monocytes precursors in vivo, M2 macrophages can be induced which in turn can exert antiinflammatory activities. In some embodiments, the antibody can be conjugated to a moiety that specifically recognizes a surface marker on the monocytes or monocytes precursors to facilitate targeted delivery of the agonist antibody, e.g., a ligand for a monocyte specific surface marker that is well known in the art (e.g., CD14). In some embodiments, a bispecific antibody comprised of the antigen-binding site of the agonist antibody and also the antigen- binding site of a second antibody recognizing a monocyte specific surface marker can be used. Such immune conjugates or bispecific antibodies can be generated using standard procedures routinely practiced in the art.
[0056] In some other embodiments, subjects with autoimmune diseases or other undesired immune responses can be treated ex vivo. In these methods, the pharmaceutical composition to be administered to a subject contains a population of M2 macrophages generated in vitro via the methods described herein. Specifically, a bone marrow sample or a population of monocytes can be first obtained from the subject in need of treatment. The cells are then contacted in vitro with a M2-inducing antibody described herein. Upon conversion into M2 macrophages and enrichment, the induced M2 macrophages are then administered to the subject in a pharmaceutical composition. Preferably, the bone marrow
cells for inducing M2 macrophage formation with the agonist antibody are obtained from the same subject into whom the resulting M2 macrophage population will be administered.
[0057] Some preferred embodiments of the invention are directed to treating human subjects afflicted with or suspected of having autoimmune disorders. Examples of autoimmune disorders and related diseases suitable for the methods of the invention include, e.g., Acute disseminated encephalomyelitis (ADEM), Addison's disease, Alopecia areata, Ankylosing spondylitis, Antiphospholipid antibody syndrome (APS), Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Bullous pemphigoid, Behcet's disease, Coeliac disease, Chagas disease, Chronic obstructive pulmonary disease, Crohn's Disease, Dermatomyositis, Diabetes mellitus type 1 ,
Endometriosis, Goodpasture's syndrome, Graves' disease, graft versus host disease
(GVHD), Guillain-Barre syndrome (GBS), Hashimoto's disease, Hidradenitis suppurativa, Kawasaki disease, Idiopathic thrombocytopenic purpura, Interstitial cystitis, Lupus erythematosus, Mixed Connective Tissue Disease, Morphea, Multiple sclerosis (MS), Myasthenia gravis, Narcolepsy, Neuromyotonia, Pemphigus vulgaris, Pernicious anaemia, Psoriasis, Psoriatic Arthritis, Polymyositis, Primary biliary cirrhosis, Rheumatoid arthritis, Schizophrenia, Scleroderma, Sjogren's syndrome, Stiff person syndrome, Temporal arteritis (aka "giant cell arteritis"), Ulcerative Colitis, Vasculitis, Vitiligo, Microscopic polyangiitis, Glomerulonephritis, and Wegener's granulomatosis.
[0058] Also provided in the invention are M2 macrophage populations generated in vitro by the methods described herein and therapeutic applications of such M2 macrophage populations. For therapeutic applications of the M2 macrophage populations, the induced cell population is preferably enriched for M2 macrophages. M2 macrophages can be first isolated from the induced cell population noted above, and then further enriched in vitro before being administered to a subject in need of treatment of a disease or disorder (e.g., autoimmune diseases). Isolation and enrichment of M2 macrophages from the induced cell population can be readily carried out with methods well known in the art. For example, activated M2 macrophages can be isolated or selected for cells expressing M2 macrophage specific markers. Such markers expressed by human M2 macrophage include, e.g., CD36 (aka "SR", scavenger receptor), MHCII, ARG-1 (arginase- 1 ), CD 14, CD 163, CD206, TGM2 (transglutaminase 2), DecoyR, IL-1R II, CD86, VEGF, TLR1 and TLR8. Enrichment can also include staining cells from the induced cell population or previously selected cells with
antibodies recognizing M2 macrophage specific markers (e.g., CD36 and ARG-1), and selecting for cells with high expression of Ml macrophage specific markers (e.g., ARG-1) and low expression of markers for other type of cells (e.g., Ml macrophage markers such as IDO-1). The M2 macrophages can also be isolated or enriched by removal of cells other than M2 macrophages in the induced cell population. Thus, human M2 macrophages may be isolated or enriched by depletion of cells displaying non-M2 macrophage markers using, e.g., antibodies targeting such markers. Examples of such markers include, e.g., CD1 lb, CD80, CD86, CD16/32, IL-1R I, TLR2, TLR4 and iNOS. Protocols reported in the literature can also be used and modified for isolation and enrichment of M2 macrophages in the methods of the present invention. See, e.g., Gabrilovich et al, Nat. Rev. Immunol. 12, 253-268, 2012, Kitani et al, Immonol. 4, 1 -7, 2014; and Yang et al, Mol. Endocrinol. 28:565-574, 2014. The separation and enrichment of M2 macrophage can employ various routinely practiced techniques, e.g., flow cytometry, fluorescence-activated cell sorting (FACS) or magnetic cell sorting using microbeads conjugated with specific antibodies. Upon enrichment, the M2 macrophage populations of the invention typically contain at least 50%, 60%, 70%, 80%, 90%, 92%, 94%, 96%, 98% or more of homogeneous or
heterogeneous M2 macrophages that express one or more of the specific M2 markers described herein.
[0059] The invention additionally provides kits or pharmaceutical combinations for converting bone marrow cells or monocyte cells into M2 macrophages. The kits typically contain one or more agonist antibodies described herein, tools and materials for isolating bone marrow cells or monocyte populations from a subject, and reagents for co-culturing monocytes or precursor cells with the agonist antibody. In some embodiments, the kits can contain the agonist antibody and a cultured monocyte cell population for generating M2 macrophages that can be applied allogeneically to subjects afflicted with autoimmune diseases or other inflammatory disorders.
[0060] The pharmaceutical compositions containing an agonist antibody or a M2 macrophage population described herein can be administered to subjects in need of treatment in accordance with standard procedures of pharmacology. Methods of administering the therapeutic compositions to a subject can be accomplished based on procedures routinely practiced in the art. See, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Co, 20th ed, 2000; Ritter et al, J. Clin. Invest. 1 16:3266-76, 2006; Iwasaki et al.
Jpn. J. Cancer Res. 88:861-6, 1997; Jespersen et al., Eur. Heart J. 1 1 :269-74, 1990; and Martens, Resuscitation 27: 177, 1994. For example, a composition containing the induced M2 macrophages are typically administered (e.g., via injection) in a physiologically tolerable medium, such as phosphate buffered saline (PBS). The isolated cells, or their engineered form as disclosed herein, should be administered to the subject in a number sufficient to inhibit the development of the disease in the subject. In some embodiments, administration of therapeutic composition is carried out by local or central injection of the cells into the subject. In some other embodiments, the administration is via a systemic route such as peripheral administration. Additional guidance for preparation and administration of the pharmaceutical compositions of the invention are described in the art. See, e.g., Goodman & Oilman's The Pharmacological Bases of Therapeutics, Hardman et al., eds., McGraw-Hill Professional (10th ed., 2001); Remington: The Science and Practice of Pharmacy, Gennaro, ed., Lippincott Williams & Wilkins (20th ed., 2003); and Pharmaceutical Dosage Forms and Drug Delivery Systems, Ansel et al. (eds.), Lippincott Williams & Wilkins (7th ed., 1999).
EXAMPLES
[0061] The following examples are provided to further illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims.
Example 1. Selection system for identifying M2 macrophage-inducing antibodies
[0062] We employed an unbiased intracellular combinatorial antibody library to simultaneously discover new targets and antibodies that induce proliferation and/or differentiation of cells that express them. The general selection scheme is illustrated in Fig. 1A. The unbiased antibody library in lentiviruses, which contains about 10s unique members, was used to infect total mouse bone marrow cells. The infected cells were plated onto soft agar to observe the formation of colonies (Fig. IB). Large colonies were harvested, and the morphology of the cells therein was determined. All colonies contained cells with the classical morphology of macrophages (Fig. 1C, D). The antibody gene integrated into the cells was recovered by PCR. One sequence was repeated in 7 colonies and this antibody was chosen for further studies. This antibody gene was reinserted into lentivirus and fresh cells were infected. These cells, now infected with a single lentivirus, also formed colonies (Fig.
I E) and contained cells with a morphology that was similar to those selected after the first round of infection. To characterize the selected antibody (named LKAb), the encoding gene was transferred to a mammalian expression vector. When the purified antibody was incubated with bone marrow, a large percentage of the cells attached to the plate and developed a macrophage morphology (Fig. IF).
Example 2. Identification of binding target of antibody LKAb
[0063] The purified LKAb antibody was incubated with an extract of total mouse bone marrow cells and the immune complexes were captured on a protein A/G column. Proteins that reacted with the antibody were identified by silver staining of SDS gels and their identity determined by mass spectrometry (Fig. 7A, B). Four candidate proteins based on the number of peptide "hits" were tested for their ability to bind to antibody LKAb (Fig. 7C). Out of the candidate antigens, only Cathepsin G (CTSG) bound to LKAb as determined by Western blotting and ELISA analyses (data not shown). Classically, CTSG is known to be secreted by activated leukocytes, but it has also been shown to be present on the surface of monocytic cells. CTSG was confirmed as the target antigen by comparing LKAb to a commercial anti-CTSG antibody using Western blotting of an extract from cells over- expressing CTSG (Fig. 2A). The commercial anti-CTSG antibody also reacted strongly with a protein from mouse bone marrow extracts that was first captured by our antibody (Fig. 2B). Moreover, the protein fraction captured by our antibody was shown to have CTSG activity (Fig. 2C). Finally, when CTSG expression was silenced using shRNA, the ability of our antibody to induce macrophage formation was markedly reduced (Fig. 2D).
Example 3. Selective induction of M2 macrophages by antibody LKAb
[0064] Mouse bone marrow cells were incubated with the selected antibody, and FACS analysis using CD1 lb and CD1 l c markers was carried out to confirm that LKAb acted in a dose dependent manner and that the induced cells were of macrophage, and not dendritic cell lineage (Fig. 3A). To determine which cell population was differentiated by our antibody, bone marrow cells were sorted according to the presence or absence of the CD1 lb marker. Only the CD 1 lb-negative population differentiated to macrophages (Fig. 3B). By contrast, M-CSF induced macrophage differentiation in both populations (Fig. 3B). FACS analysis using the Ml markers CD16/32, CD86, and the M2 markers CD36 (Scavenger receptor),
MHCII, and CD 14, showed that the macrophages induced by the antibody were mostly of the M2 type (Fig. 3C). The high selectivity of our antibody for induction of M2 macrophages was confirmed by qRT-PCR analysis comparing the ability of the cells induced by either LKAb or M-CSF to express the Ml marker IDOl or the M2 marker ARG-1. Cells induced by our antibody displayed high expression of ARG-1 and limited expression of IDO-1, whereas cells induced with M-CSF showed high expression of IDOl and only low expression of ARG-1 (Fig. 3D).
[0065] Expression of the cytokine IL-10 is another feature of M2 macrophages. To determine the in vivo effect of our antibody on IL-10 production, we injected LKAb i.p. into C57BL/6 and BALB/c mice and found significantly higher levels of IL-10 in treated compared to control mice (Fig. 3E). To study the activation of signaling pathways, fresh mouse bone marrow cells were treated with the antibody, and cell lysates were assessed by Western blotting using anti-phospho p38, ERK and AKT. ERK and AKT were activated to some extent, but p38 was strongly activated, consistent with its known role in M2 macrophage polarization (Fig. 8).
Example 4. Mechanistic studies
[0066] While CTSG is located on the surface of macrophages and polymorphonuclear leukocytes, it lacks a signal transduction domain, and thus its role in cell activation is indirect. Nevertheless, there is an increasing awareness of the role that CTSG plays in the regulation of important cell surface receptors. In particular, CTSG has been reported to regulate monocyte activation by down-regulation of CD 14, which is a critical co-receptor for TLR4 in the innate immune system and is involved in differentiation of cells in the macrophage lineage.
[0067] Given its role in the innate immune system and the high concentration of CD 14 on the surface of monocytes, we assessed CD 14 involvement in differentiation of macrophages by our antibody. Bone marrow cells from CTSG (-/-), CD 14 (-/-) and wild- type mice were incubated with LKAb, and FACS analysis using CD14 and F4/80 markers showed that this antibody increased CD 14 expression in wild-type cells (Fig. 4A), presumably because the activity of CTSG was inhibited. However, no increase in CD14 was observed in the CTSG (-/-) or CD14 (-/-) cells (Fig. 4A). In addition, the ability of the antibody to induce the general macrophage marker F4/80 was significantly decreased in
bone marrow cells from CTSG (-/-) or CD 14 (-/-) mice (Fig. 4A). Consistent with these results, we found that LKAb inhibited CTSG activity by 50 % (Fig. 4B).
[0068] Since CD 14 and TLR4 are co-receptors, we studied whether TLR4 was also required for LKAb-mediated macrophage differentiation. Using bone marrow cells from wild-type and TLR4 (-/-) mice, we showed that the cell polarizing function of our antibody was TLR4-independent (Fig. 9). The finding that LKAb required CD 14 but not TLR4 to induce macrophage differentiation left open the question of the mechanism of signal transduction. Unlike TLR4, CD14 does not have a signal transduction domain. However, recently dendritic cells have been reported to be activated through a NFAT signaling pathway that is dependent on CD14 but independent of TLR4. Therefore, we used NFAT knockout mice to determine whether this pathway plays a role in macrophage differentiation induced by our antibody. Bone marrow cells from NFATcl (-/-) and NFATc2flox flox: CD4Cre mice were incubated with LKAb and analyzed by FACS using the CD 14 and F4/80 markers. We found that macrophage differentiation was impaired in NFATcl (-/-) mice (Fig. 4A). As expected, NFAT inactivation in non-macrophage cells (such as CD4 expressing T cells and dendritic cells) had no consequence on macrophage differentiation by our antibody (Fig. 4A). Thus, we have a picture of CTSG's role in macrophage polarization suggesting that this molecule operates through CD 14 and NFAT to regulate macrophage activation and differentiation (Fig. 4C).
Example 5. Inducing M2 macrophages from human bone marrow
[0069] Since the human and mouse CTSG proteins are highly homologous, we wished to test the ability of our antibody to induce macrophage formation from human total bone marrow. As in the mouse, LKAb selectively induced M2 macrophages, as evidenced by a large increase in cells bearing the CD 14, CD206 and CD200R markers (Fig. 5).
Example 6. LKAb treatment reduces systemic autoimmunity
[0070] We next investigated whether this antibody could be used therapeutically in lupus, an autoimmune disease in which Ml macrophage infiltration appears to significantly contribute to end-organ pathology. For this experiment, we used MRL-Fas/lpr mice, which develop lupus-like manifestations with high titers of anti-nuclear autoantibodies, immune complex glomerulonephritis (GN), and early mortality primarily due to defective Fas-
mediated T and B cell apoptosis. Treatments with LKAb (75 μg/mouse i.p. two times/week) were initiated at 6 weeks of age, and the experiment was terminated at 20 weeks of age, when >50% of the control (PBS-treated) mice were dead and the remaining exhibited signs of discomfort due to advanced disease. The results showed significant reductions in disease parameters in LKAb-treated mice compared to controls. Thus, titers of anti-chromatin IgG2a autoantibodies, the main isotype induced in this model, were reduced in the serum of treated mice (Fig. 6A). The treatment also significantly inhibited progression of Iymphadenopathy (Fig. 6B). Moreover, at 20 weeks of age, treated mice had significantly reduced GN scores (Fig. 6C) and, accordingly, extended survival (Fig. 6D).
Example 7. Materials and methods
[0071] Mouse strains and cell lines: The following mouse strains were used: C57BL/6J, BALB/c, C3H/HeJ, C3H/HeOuJ, C57BL/10ScNJ, B6.129S4-CD14tm l fm/J and MRL/MPJ- Fas (lpr)/J (The Jackson laboratory). CTSG knockout mice were the generous gift of Dr. Christine Pham (Washington University, St. Louis, MO). NFATcl (-/-) and ΝΡΑΤϋ2Ποχ/Ποχ: CD4Cre mice were the generous gift of Dr. Anjana Rao (La Jolla institute for allergy and immunology). The F1EK293T cell line was maintained in DMEM medium containing 10% FCS, penicillin and streptomycin (Gibco-Invitrogen). The HEK293F cell line was maintained in Freestyle 293 Expression Media with 4 mM Glutamax (Gibco-Invitrogen). For inducing M2 macrophage with the LKAb antibody, human total bone marrow cells (All- Cells) were cultured in StemSpan serum-free media with cytokine cocktail (STEMCELL Technologies) and the antibody (10 μg/ml) at 37°C. The mouse bone marrow cells were similarly cultured, except that the cells were in the DMEM/F12 medium containing 10% FCS, penicillin and streptomycin (Gibco-Invitrogen). Mice were housed and handled according to protocols approved by the Institutional Animal Care and Use Committee at The Scripps Research Institute.
[0072] Combinatorial antibody library and lentivirus: Single-Chain Fv (ScFv) genes were obtained from a naive human combinatorial antibody library (1 χ 101 1 library diversity). ScFv genes were sub-cloned into a lentiviral vector. Lentivirus was produced in HEK293T cells by co-transfection of lentiviral vectors with the pCMVD8.91 and pVSVg viral packaging vectors at a ratio of 1 : 1 : 1. Supernatants containing virus were collected at 48 h post-transfection. Cell debris was removed by centrifugation and filtration through a 0.22-
μιη polyethersulfone membrane filter unit from Millipore. The titer of the lentivirus preparation was determined using a Lenti-X p24 ELISA (Clontech). The virus preparations were aliquoted and frozen at -80 °C.
[0073] Transduction and colony forming cell assay: The bone marrow cells were incubated with lentivirus for 3 days at 37 °C. Selection of agonist antibodies was done by a Colony-Forming Cell Assay using Methylcellulose-Based Media. Bone marrow cells were transduced with the lentiviral antibody library at a multiplicity of infection of 2 and added to methylcellulose media at the final concentrations of 1.27% methylcellulose and ~3 χ 104 cells/mL. A total of 1.5 mL of cell suspension was added to 35-mm-diameter dishes. The cells in soft agar were cultured for 2 wk. The colonies were harvested with the aid of a micromanipulator (Sutter Instruments). The antibody genes from each colony were amplified by PCR with primer pairs customized for our lentiviral vector. The amplified antibody genes were analyzed by electrophoresis and recovered.
[0074] Purification of scFv-Fc proteins: For single antibodies, the antibody expression vector was transfected into HEK293F cells. Antibodies from the pooled supernatants were purified using HiTrap Protein G HP columns with an AKTAxpress purifier (GE). The buffer was exchanged to Dulbecco's PBS (pH 7.4) and stored at 4 °C. The vector encoding the ScFv-Fc tag fusion protein was transfected into HEK293F cells for transient expression.
[0075] Immunoprecipitation and Mass Spectrometry: For immunoprecipitation, mouse bone marrow cells were prepared and solubilized in lysis buffer. The lysates were incubated with LKAb for 2 hours at 4°C, followed by incubation with 50 μΐ of protein G-Sepharose beads (Pierce). The eluent was introduced into the linear trap quadrupole mass spectrometer from a nano-ion source with a 2-kV electrospray voltage. The analysis method consisted of a full MS scan with a range of 400-2,000 m/z followed by data-dependent MS/MS on the three most intense ions from the full MS scan. The raw data from the linear trap quadrupole were searched using the IPI human FASTA database with the MASCOT
(www.matrixscience.com) search engine.
[0076] Western blot: Bone marrow cells were washed with PBS and then lysed in lysis buffer (50 mM Hepes, pH 7.2, 150 mM NaCl, 50 mM NaF, 1 mM Na3V04, 10% glycerol, 1% Triton X-100). The lysates were then centrifuged at 20,000 χ g for 15 min at 4 °C. The proteins were denatured in Laemmli sample buffer (5 min at 95 °C), separated by
SDS/PAGE, and transferred to nitrocellulose membranes using the iBlot blotting system
(Invitrogen). Membranes were blocked in phosphate buffered saline with Tween 20 (PBST) containing 5% BSA for 30 min before being incubated with antibodies for 3 h. Cathepsin G antibody (Santa Cruz Biotechnology) was used for identification. After washing the membranes several times with PBST, the blots were incubated with horseradish peroxidase- conjugated anti-goat or anti-rabbit antibody for 1 h. The membranes were then washed with PBST and developed by ECL. Phosphorylation was performed with phospho-AKT, ERK and p38 (Cell Signaling Technology).
[0077] Silencing CTSG mRNA: Mouse CTSG shRNAs (Santa Cruz Biotechnology) used for producing lentiviral particles contain three target-specific constructs designed to knock down gene expression. Mouse bone marrow cells were infected with Lentivirus CTSG shRNA and cultured with LKAb or M-CSF for 6 days.
[0078] Flow cytometry and cell sorting: Cells were stained with anti-mouse or human CD1 lb, CD1 lc, CD14, F4/80, CD16/32, CD36, CD86, MHCII, CD206, CD64, and
CD200R (BD Biosciences). Stained cells were analyzed with a LSRII flow cytometer (Becton Dickinson). To obtain CD1 lb positive and negative bone marrow cells, CD1 lb+
8 8 microbeads (15 μ1/10 cells; Miltenyi Biotech) were added to a suspension of 10 cells/mL of separation buffer and incubated for 15 minutes on ice followed by washing. The cells were resuspended in separation buffer (500 μ1/108 cells), run through a SuperMACS II Separation Unit equipped with an MS column (Miltenyi Biotec), washed 3 times with buffer (500 μΐ), and flow-through cells were collected under pressure.
[0079] Real Time Quantitative RT-PCR: Macrophage were obtained from bone marrow cells cultured with LKAb antibody or M-CSF, RNA was extracted (Qiagen) and cDNA synthesized (Invitrogen). PCR was performed in triplicate using 400 ng cDNA, the RT SYBR Green supermix (Bio-Rad Laboratories), primer sets specific for mouse Arg-1 or IDOl gene sequences, and a CI 000 Thermal cycler (Bio-Rad Laboratories).
[0080] CTSG enzymatic activity: To monitor enzyme activities, we used an assay based on Cathepsin G-mediated cleavage of a specific substrate and release of the dye group pNA (4-Nitroaniline). This assay was performed with mouse bone marrow lysates that were incubated with LKAb or CTSG inhibitor.
[0081] Cytokine assay: Cytokines were quantified in serum collected from individual mice using a mouse cytokine magnetic bead panel (EMD Millipore) according to
manufacturer's instructions.
[0082] Treatment with isolated antibody: MRL-Faslpr mice were treated i.p. with LKAb (75μg/mouse) two times per week. Treatments were initiated at 6 weeks of age and the experiment was terminated at 20 weeks of age. Total and anti-chromatin serum IgG subclasses were assessed by ELISA using 96-well plates coated with goat anti-mouse IgG (Jackson ImmunoResearch Laboratories) and mouse chromatin, respectively. Bound antibodies were detected using alkaline phosphatase-conjugated goat antibodies (Caltag Laboratories) to mouse IgG or IgG2a, the main autoantibody subclass in this model.
Standard curves were generated using calibrated mouse serum (Accurate Chemical and Scientific Company).
[0083] Statistical analysis: The data are expressed as the means ± SE. Statistical analysis was performed using the Student t test or by one-way analysis of variance and the post hoc test. The groups were analyzed by unpaired two-tailed Student's t test. Survival was analyzed by Kaplan-Meier plot and log rank test. P values of <0.05 were considered significant.
***
[0084] LKAb antibody amino acid sequence
[0085] scFv sequence (SEQ ID NO: 1)
[0086] MAQVQLVQSG AEVKKPGASV KVSCKASGYT FTSYYMHWVR
QAPGQGLEWM GGIIPIFGTG NYAQKFQGRV TITADESTST AYMELSSLRS EDTAVYYCAR EEEQQFSLDY WGQGTLVTVS SGGGGGLS NF MLTQPHSVSE SPGKTVTISC TRSSGSIASN SVHWYQQRPG SAPTTVISEN NQRPSGVPDR FSGSIDSSSN SASLTISGLK TEDEADYYCQ SYDSNFHWVF GGGTQLTVLG
[0087] Heavy chain variable region sequence (SEQ ID NO:2)
[0088] MAQVQLVQSG AEVKKPGASV KVSCKASGYT FTSYYMHWVR
QAPGQGLEWM GGIIPIFGTG NYAQKFQGRV TITADESTST AYMELSSLRS EDTAVYYCAR EEEQQFSLDY WGQGTLVTVS S
[0089] Light chain variable region sequence (SEQ ID NO:3)
[0090] NF MLTQPHSVSE SPGKTVTISC TRSSGSIASN SVHWYQQRPG
SAPTTVISEN NQRPSGVPDR FSGSIDSSSN SASLTISGLK TEDEADYYCQ SYDSNFHWVF GGGTQLTVLG
[0091] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
[0092] All publications, databases, GenBank sequences, patents, and patent applications cited in this specification are herein incorporated by reference as if each was specifically and individually indicated to be incorporated by reference.
Claims
1. An isolated or purified anti-Cathepsin G (CTSG) antibody, which has the same binding specificity as that of a reference antibody comprising (1) heavy chain CDRl , CDR2 and CDR3 sequences respectively shown in GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and (2) light chain CDRl, CDR2 and CDR3 sequences respectively shown in SGSIASNS (SEQ ID NO:7), ENN, and QSYDSNFHWV (SEQ ID NO:8).
2. The antibody of claim 1 , comprising heavy chain CDRl, CDR2 and CDR3 sequences that are substantially identical to GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6), respectively; and light chain CDRl, CDR2 and CDR3 sequences that are substantially identical to SGSIASNS (SEQ ID NO:7), ENN, and QSYDSNFHWV (SEQ ID NO:8), respectively.
3. The antibody of claim 1 , comprising heavy chain CDRl , CDR2 and CDR3 sequences that are respectively identical to GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and light chain CDRl , CDR2 and CDR3 sequences that are respectively identical to SGSIASNS (SEQ ID NO:7), ENN, and QSYDSNFHWV (SEQ ID NO:8) (SEQ ID NO:8).
4. The antibody of claim 1, comprising heavy chain and light chain variable region sequences that are substantially identical to SEQ ID NO:2 and SEQ ID NO:3, respectively.
5. The antibody of claim 1, comprising heavy chain and light chain variable region sequences that are at least 90% or 95% identical to SEQ ID NO:2 and SEQ ID NO:3, respectively.
6. The antibody of claim 1, comprising heavy chain and light chain variable region sequences show in SEQ ID NO:2 and SEQ ID NO:3, respectively.
7. The antibody of claim 1, comprising an amino acid sequence that is substantially identical to SEQ ID NO: l .
8. The antibody of claim 1, comprising an amino acid sequence that is at least 90% or 95% identical to SEQ ID NO: 1.
9. The antibody of claim 1 , comprising a scFv antibody fragment shown in
SEQ ID NO: l .
10. A method for inducing formation of anti-inflammatory M2 macroph comprising contacting a population of bone marrow cells or monocytes with an anti- Cathepsin G antibody under conditions sufficient to induce formation of anti-inflammatory macrophage, wherein the anti-Cathepsin G antibody has the same binding specificity as that of a reference antibody comprising (a) heavy chain CDRl , CDR2 and CDR3 sequences respectively shown in GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and (b) light chain CDRl, CDR2 and CDR3 sequences respectively shown in SGSIASNS (SEQ ID NO: 7), ENN, and QSYDSNFHWV (SEQ ID NO:8).
11. The method of claim 10, wherein the bone marrow cells are human bone marrow cells.
12. The method of claim 10, wherein the contacting occurs in vitro by culturing the population of bone marrow cells or monocytes in the presence of the anti- Cathepsin G antibody.
13. The method of claim 12, wherein culturing is for about 4 to 20 days.
14. The method of claim 12, further comprising isolating CD1 l b- cells from the cultured cell population.
15. The method of claim 12, further comprising detecting in the cultured cell population at least one cellular marker expressed by M2 macrophage.
16. The method of claim 15, wherein the at least one cellular marker expressed by M2 macrophage is CD36, MHCII, CD14, or ARG-1.
17. The method of claim 10, wherein the contacting occurs in vivo in a subject afflicted with an autoimmune disease.
18. The method of claim 10, wherein the anti-Cathepsin G antibody comprises heavy chain CDRl, CDR2 and CDR3 sequences that are respectively identical to GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and light chain CDRl , CDR2 and CDR3 sequences that are respectively identical to SGSIASNS (SEQ ID NO:7), EN , and QSYDSNFHWV (SEQ ID NO:8) (SEQ ID NO:8).
19. The method of claim 10, wherein the anti-Cathepsin G antibody comprises heavy chain and light chain variable region sequences that are substantially identical to SEQ ID NO:2 and SEQ ID NO:3, respectively.
20. The method of claim 10, wherein the anti-Cathepsin G antibody comprises heavy chain and light chain variable region sequences show in SEQ ID NO:2 and SEQ ID NO:3, respectively.
21. The method of claim 10, wherein the anti-Cathepsin G antibody comprises an amino acid sequence that is substantially identical to SEQ ID NO: l .
22. The method of claim 10, wherein the anti-Cathepsin G antibody comprises a scFv antibody fragment shown in SEQ ID NO: 1.
23. A population of anti-inflammatory M2 macrophage produced by the method of claim 10.
24. A method for treating or ameliorating the symptoms of an autoimmune disease in a subject, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an anti-Cathepsin G antibody, thereby treating or ameliorating the symptoms of the autoimmune disease in the subject, wherein the anti-Cathepsin G antibody has the same binding specificity as that of a reference antibody
comprising (a) heavy chain CDR1 , CDR2 and CDR3 sequences respectively shown in GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO:5), and AREEEQQFSLDY (SEQ ID NO:6); and (b) light chain CDR1 , CDR2 and CDR3 sequences respectively shown in SGSIASNS (SEQ ID NO:7), ENN, and QSYDSNFHWV (SEQ ID NO:8).
25. The method of claim 24, wherein the autoimmune disease is lupus.
26. The method of claim 24, wherein the anti-Cathepsin G antibody comprises heavy chain CDR1, CDR2 and CDR3 sequences that are respectively identical to GYTFTSYY (SEQ ID NO:4), IIPIFGTG (SEQ ID NO: 5), and AREEEQQFSLDY (SEQ ID NO:6); and light chain CDR1, CDR2 and CDR3 sequences that are respectively identical to SGSIASNS (SEQ ID NO:7), ENN, and QSYDSNFHWV (SEQ ID NO:8) (SEQ ID NO:8).
27. The method of claim 24, wherein the anti-Cathepsin G antibody comprises heavy chain and light chain variable region sequences that are substantially identical to SEQ ID NO:2 and SEQ ID NO:3, respectively.
28. The method of claim 24, wherein the anti-Cathepsin G antibody comprises heavy chain and light chain variable region sequences show in SEQ ID NO:2 and SEQ ID NO:3, respectively.
29. The method of claim 24, wherein the anti-Cathepsin G antibody comprises an amino acid sequence that is substantially identical to SEQ ID NO: 1.
30. The method of claim 24, wherein the anti-Cathepsin G antibody comprises a scFv antibody fragment shown in SEQ ID NO: 1.
31. A method for obtaining anti-inflammatory M2 macrophages from a population of bone marrow cells or monocytes, comprising (a) introducing into the bone marrow cells or monocytes a plurality of vectors expressing a library of antibodies, (b) culturing the cells harboring the vectors under conditions to express the library of antibodies, and (c) selecting one or more macrophages from the cells expressing the library of antibodies; thereby obtaining M2 macrophages from the population of bone marrow cells or monocytes.
32. The method of claim 31 , wherein the library of antibodies are unbiased.
33. The method of claim 31, wherein the antibodies are scFvs.
34. The method of claim 31, wherein the vectors are lentiviral vectors.
35. The method of claim 31, wherein the cells are CD34+ bone marrow cells.
36. The method of claim 31, wherein the M2 macrophages are selected based on morphology.
37. The method of claim 31 , wherein the M2 macrophages are selected based on expression of surface markers.
38. The method of claim 31, further comprising isolating the antibody- expressing vectors from the selected M2 macrophages.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016324021A AU2016324021A1 (en) | 2015-09-15 | 2016-09-12 | Antibodies for generating anti-inflammatory macrophage and related uses |
EP16847105.0A EP3349768A4 (en) | 2015-09-15 | 2016-09-12 | Antibodies for generating anti-inflammatory macrophage and related uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562218785P | 2015-09-15 | 2015-09-15 | |
US62/218,785 | 2015-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017048629A1 true WO2017048629A1 (en) | 2017-03-23 |
Family
ID=58289788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/051290 WO2017048629A1 (en) | 2015-09-15 | 2016-09-12 | Antibodies for generating anti-inflammatory macrophage and related uses |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3349768A4 (en) |
AU (1) | AU2016324021A1 (en) |
WO (1) | WO2017048629A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116445407A (en) * | 2023-06-16 | 2023-07-18 | 广州正源生物技术有限公司 | Extraction and amplification culture method of placenta macrophages |
WO2023146860A1 (en) * | 2022-01-28 | 2023-08-03 | The George Washington University | Compositions for and methods of treating a subject having inflammation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060272041A1 (en) * | 2001-09-24 | 2006-11-30 | Wisotzkey Robert G | Cathepsin G (CTSG) Disruptions, Compositions and Methods Relating Thereto |
US7786269B2 (en) * | 2001-12-04 | 2010-08-31 | Dana-Farber Cancer Institute, Inc. | Antibody to latent membrane proteins and uses thereof |
US20110117086A1 (en) * | 2009-10-16 | 2011-05-19 | Bioréalités S.A.S. | Monoclonal antibodies to progastrin and their uses |
US20130142760A1 (en) * | 2010-08-18 | 2013-06-06 | Cedars-Sinai Medical Center | Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer |
US20140114054A1 (en) * | 2011-05-09 | 2014-04-24 | University Of Miyazaki | Antibody capable of specifically recognizing transferrin receptor |
-
2016
- 2016-09-12 AU AU2016324021A patent/AU2016324021A1/en not_active Abandoned
- 2016-09-12 EP EP16847105.0A patent/EP3349768A4/en not_active Withdrawn
- 2016-09-12 WO PCT/US2016/051290 patent/WO2017048629A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060272041A1 (en) * | 2001-09-24 | 2006-11-30 | Wisotzkey Robert G | Cathepsin G (CTSG) Disruptions, Compositions and Methods Relating Thereto |
US7786269B2 (en) * | 2001-12-04 | 2010-08-31 | Dana-Farber Cancer Institute, Inc. | Antibody to latent membrane proteins and uses thereof |
US20110117086A1 (en) * | 2009-10-16 | 2011-05-19 | Bioréalités S.A.S. | Monoclonal antibodies to progastrin and their uses |
US20130142760A1 (en) * | 2010-08-18 | 2013-06-06 | Cedars-Sinai Medical Center | Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer |
US20140114054A1 (en) * | 2011-05-09 | 2014-04-24 | University Of Miyazaki | Antibody capable of specifically recognizing transferrin receptor |
Non-Patent Citations (4)
Title |
---|
HAN, KH ET AL.: "An Agonist Antibody that Blocks Autoimmunity by Inducing Anti-Inflammatory Macrophages.", FASEB JOURNAL., vol. 30, no. 2, 19 October 2015 (2015-10-19), pages 738 - 747, XP055368761 * |
ITALIANI, P ET AL.: "From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation.", FRONTIERS IN IMMUNOLOGY., vol. 5, no. 514, 17 October 2014 (2014-10-17), pages 1 - 22, XP055368757 * |
MIA, S ET AL.: "An optimized Protocol for Human M2 Macrophages using M-CSF and . IL -4/ IL -10/TGF-beta Yields a Dominant Immunosuppressive Phenotype.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY ., vol. 79, no. 5, May 2014 (2014-05-01), pages 305 - 314, XP055163193 * |
See also references of EP3349768A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023146860A1 (en) * | 2022-01-28 | 2023-08-03 | The George Washington University | Compositions for and methods of treating a subject having inflammation |
CN116445407A (en) * | 2023-06-16 | 2023-07-18 | 广州正源生物技术有限公司 | Extraction and amplification culture method of placenta macrophages |
CN116445407B (en) * | 2023-06-16 | 2023-09-08 | 广州正源生物技术有限公司 | Extraction and amplification culture method of placenta macrophages |
Also Published As
Publication number | Publication date |
---|---|
AU2016324021A1 (en) | 2018-04-12 |
EP3349768A1 (en) | 2018-07-25 |
EP3349768A4 (en) | 2019-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210095012A1 (en) | Anti-semaphorin 3a antibody and treatment of alzheimer's disease and inflammatory immune diseases using same | |
KR102362609B1 (en) | Anti-garp protein and uses thereof | |
JP2021184710A (en) | Antibodies that bind to envelope glycoproteins of severe fever with thrombocytopenia virus and uses thereof | |
NZ590033A (en) | Interleukin-1alpha antibodies and methods of use | |
US9944700B2 (en) | Notch2 binding molecules for treating respiratory diseases | |
EP3024849A2 (en) | Novel antibodies for the diagnosis and treatment of rheumatoid arthritis | |
CN114075289A (en) | anti-CD 73 antibodies and uses thereof | |
WO2016090035A2 (en) | Modulators of activin and methods for modulating immune responses and t follicular helper cells | |
WO2017048629A1 (en) | Antibodies for generating anti-inflammatory macrophage and related uses | |
WO2016205784A1 (en) | Methods and compositions for producing activated natural killer cells and related uses | |
JP6742581B2 (en) | IPS/ES cell-specific antibody having target cytotoxic activity and use thereof | |
CN107849134B (en) | Methods of mediating cytokine expression with anti-CCR 4 antibodies | |
EP4386000A1 (en) | Recombinant anti-human-cd25 antibody and use thereof | |
JP2019508415A (en) | Anti-citrullinated HLA polypeptide antibody and use thereof | |
CN114258402A (en) | anti-CD123 antibodies, anti-CD123 chimeric antigen receptors, and anti-CD123 chimeric antigen receptor T cells | |
US20200140851A1 (en) | Methods and Compositions Related to In Vivo Selection of Functional Molecules | |
US20230159652A1 (en) | Transferrin receptor 1 targeting for carcinogenesis prevention | |
CN116948023B (en) | Tau protein antibodies and uses thereof | |
CN113698480B (en) | Group of IL-23 monoclonal antibodies and medical application thereof | |
CN112062848B (en) | anti-CD47 monoclonal antibody and application thereof | |
JP7181523B2 (en) | Novel antibody that specifically recognizes sugar chain as epitope and use thereof | |
Noto | The Role of Type 2 Cytokines and Mast Cells in the Development of Gastric Metaplasia | |
KR20240038198A (en) | Antibody for inducing insulin-secreting beta-cell differentiation and composition for preventing or treating metabolic syndromes containing the same | |
CN114671950A (en) | Humanized antibody targeting CD47 and application thereof | |
CN117886940A (en) | Humanized anti-human CD132 monoclonal antibody and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16847105 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016324021 Country of ref document: AU Date of ref document: 20160912 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016847105 Country of ref document: EP |